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ZUSAMMENFASSUNG  
 
Kardiovaskuläre Erkrankungen sind immer noch die führende Todesursache bei Frauen und 
Männern in der westlichen Welt. Es gibt verschiedene Faktoren wie viszerale Adipositas, 
Hypertonie, Insulinresistenz und atherogene Dyslipidämie, welche zum Risiko des 
kardiovaskulären Todes substantiell beitragen. Low density lipoprotein (LDL) Moleküle initiieren 
die frühe Atherogenese. Eines der atherogensten Lipoproteine ist Lipoprotein(a) [Lp(a)], das aus 
einem LDL-ähnlichem Partikel und dem Apolipoprotein(a) [Apo(a)] besteht. Zirkulierende Lp(a) 
Serumspiegel jedoch sind bemerkenswerterweise gegen gewöhnliche lipidsenkende Therapien 
eher resistent. Eine Ausnahme ist Niazin, welches erhöhte Lp(a) Serumspiegel effektiv senken 
kann. Aufgrund von schweren Nebenwirkungen wurde Niazin allerdings in Europa bereits im 
letzten Jahr vom Markt genommen. Somit sind derzeit neben der sehr kostenintensiven, 
aufwändigen und zudem noch invasiven Lipid-Aphärese keine effektiven Therapiemöglichkeiten 
für die Reduktion von Lp(a) verfügbar. Aus diesem Grund werden alternative gut verträgliche 
und geeignete Therapieansätze benötigt, um erhöhte Lp(a) Serumspiegel zu senken. In einer 
jüngsten klinischen Studie wurde gezeigt, dass die Inhibition des Interleukin-6 (IL-6) Signalweges 
durch Tocilizumab (TCZ) die Lp(a) Serumspiegel in Patienten mit rheumatoider Arthritis (RA) bis 
zu 50% erniedrigt. Folglich könnte man davon ausgehen, dass TCZ als neuer, 
erfolgversprechender Ansatz für die Behandlung von erhöhtem Lp(a) betrachtet werden kann. 
Um auf Kausalität zu prüfen und mögliche Störfaktoren innerhalb der klinischen Studie zu 
exkludieren, intendierte diese Arbeit, die Apo(a)-induzierende Fähigkeit von IL-6 und die Apo(a)-
inhibierende Fähigkeit von TCZ auf molekularer Ebene im humanen Model in vivo und in vitro 
weiter zu untersuchen. Um diese Fragestellung zu bearbeiten, wurden molekulare, zelluläre und 
physiologische Experimente sowie auch Assoziationsstudien kombiniert, um regulatorische 
Determinanten von Lp(a) im Menschen zu analysieren. 
Z u s a m m e n f a s s u n g  
 
 
In der vorliegenden Arbeit wurde gezeigt, dass der Lp(a)-reduzierende Effekt durch TCZ 
spezifisch für IL-6 ist, da eine anti-TNF-α Therapie die Lp(a) Serumspiegel in RA Patienten nicht 
veränderte. Weiterhin wurden signifikante Assoziationen zwischen Determinanten wie IL-6, dem 
C-reaktivem Protein (CRP), dem Body Mass Index sowie auch dem Insulinresistenz-Index 
(HOMA) und Lp(a) in 1153 Probanden gefunden. Unter diesen waren IL-6 und Akut-Phase-Protein 
CRP am stärksten mit Lp(a) assoziiert. Mechanistische Zellkulturstudien zu IL-6 und Apo(a) 
bestätigten, dass  IL-6 Apo(a) spezifisch induziert, und dass TCZ die IL-6-induzierte Apo(a) 
Expression auf Promoter, Transkript und Proteinebene in kultivierten Hepatozyten aufhebt. Da 
bekannt ist, dass der Promoter des Apo(a)-Gens sechs IL-6 responsive Elemente (IL-6-RE) 
besitzt, wurde der Apo(a) Promoter trunkiert, um explizit zu untersuchen, welche/s der sechs IL-
6-RE für die Apo(a) Transkription verantwortlich ist/sind. Hierbei ergab sich, dass hauptsächlich 
IL-6-RE 6 die Apo(a) Transkription reguliert. Die IL-6-abhängige Bindung des 
Transkriptionsfaktors STAT3 an IL-6-RE 6 wurde ebenfalls in einem nachfolgenden EMSA 
Experiment verifiziert. Zusätzlich wurde demonstriert, dass nicht nur der Apo(a), sondern auch 
der LDL Metabolismus durch IL-6 und TCZ beeinflusst wird. 
Zusammenfassend lässt sich sagen, dass diese Arbeit zahlreiche Beweise liefert, dass (1) IL-6 
spezifisch Apo(a) und letztlich Lp(a) auf verschiedenen molekularen Ebenen in vivo und in vitro 
induziert und dass dadurch (2) eine IL-6 Rezeptor Blockierung durch TCZ eine vielversprechende 
zukünftige Therapieoption sein kann, um erhöhte Lp(a) Serumspiegel zu behandeln und um das 
kardiovaskuläre Risiko in betroffenen Patienten zu reduzieren. TCZ würde daraus folgend eine 
geeignete Alternative zur aufwendigen Lipid-Aphärese darstellen. 
S u m m a r y  
 
 
SUMMARY  
 
Cardiovascular disease is still the leading cause of death in the western world in men and 
women. There are several factors such as visceral obesity, hypertension, insulin resistance and 
atherogenic dyslipidemia which substantially contribute to a risk of cardiovascular death. Low-
density lipoprotein (LDL) molecules initiate early atherogenesis. One of the most atherogenic 
lipoproteins is lipoprotein(a) [Lp(a)], which consists of a LDL-like particle and apolipoprotein(a) 
[apo(a)]. However, circulating levels of Lp(a) are remarkably resistant to common lipid lowering 
therapies. One exception to effectively lower Lp(a) levels is niacin. However, due to severe side 
effects, niacin was recently withdrawn from the market in Europe. Thus, there are currently no 
effective treatments available for the reduction of Lp(a) apart from lipid aphaeresis which is 
costly and labor-intensive. For this reason, alternative well-tolerated and more convenient 
therapeutic approaches are required to decrease elevated Lp(a) serum levels. In a recent clinical 
study it was shown that inhibition of interleukin-6 (IL-6) signaling by tocilizumab (TCZ) lowers 
Lp(a) serum levels in rheumatoid arthritis (RA) patients by up to 50 %. Therefore, one may 
consider TCZ as a new promising approach for lowering Lp(a). In order to prove for causality and 
to exclude possible confounders within the clinical study this thesis aims to further examine the 
ability of IL-6 to induce hepatic apo(a) expression and the ability of TCZ to inhibit apo(a) on a 
molecular level in humans in vitro and in vivo. To address this question, molecular, cellular and 
physiological experiments as well as human association studies were combined to analyze 
regulatory determinants of Lp(a) in humans. 
In the present thesis it was shown that the Lp(a) lowering effect of TCZ is specific to IL-6 
signaling as anti-TNF-α therapy did not alter Lp(a) serum levels in RA patients. Moreover, 
significant associations between determinants such as IL-6, C-reactive protein (CRP), Body Mass 
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Index as well as homeostasis model assessment-estimated insulin resistance and Lp(a) in n=1153 
human subjects were found. Amongst those, IL-6 and IL-6 response reactant CRP were strongest 
associated with Lp(a). Mechanistic cell culture studies on IL-6 and apo(a) revealed that IL-6 
specifically induced apo(a) and that TCZ inhibited the IL-6-induced apo(a) expression on 
promoter, transcript and protein level in cultured hepatocytes. As it is known that the apo(a) 
promoter contains six IL-6 responsive elements (RE), the apo(a) promoter was truncated to 
explicitly investigate which IL-6 RE(s) is/are responsible for the apo(a) transcription. This analysis 
suggested that solely IL-6 RE 6 confers major apo(a) transcription. IL-6-dependent binding of 
transcription factor STAT3 to IL-6 RE was verified in subsequent EMSA experiments. In addition, 
not only apo(a) but also LDL metabolism were demonstrated to be affected by IL-6 and TCZ. 
In conclusion, the present thesis provides several lines of evidence that (1) IL-6 specifically 
induces apo(a) and eventually Lp(a) on different molecular levels in vivo and in vitro and that 
therefore (2) IL-6 blockade by TCZ might be a promising future therapy to treat elevated Lp(a) 
serum levels and to reduce CVD risk in affected patients. Hence, TCZ might be a convenient 
alternative to the costly, labor-intensive and invasive lipid aphaeresis. 
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1. INTRODUCTION  
 
 
Cardiovascular disease (CVD) is still the leading cause of death in the western world in men and 
women, despite recent progress regarding its treatment. It is accounting for one of three deaths 
in the United States today [1]. In the mid-20th century, the Framingham Heart Study revealed the 
epidemiology of atherosclerotic CVD and already identified smoking, obesity, glucose 
intolerance, high cholesterol levels and many more factors as substantially contributing to a risk 
of cardiovascular death [2].  
All these factors, except for smoking, also represent the metabolic syndrome (MetS) (also 
referred to as syndrome X) and will be demonstrated in more detail in paragraph 1.1.  
 
 
1.1 Metabolic Syndrome 
 
1.1.1 Definition 
 
The MetS is a complex disorder with high socioeconomic cost that is considered a worldwide 
epidemic. This is mostly due a modern lifestyle, namely the hypercaloric diet and the physical 
inactivity. MetS is defined by a combination of cardiovascular risk determinants, including 
obesity, insulin resistance, hypertension, and lipid abnormalities for example elevated 
triglycerides (TG) and apolipoprotein B (apoB) -containing lipoproteins, increased free fatty acids 
(FFA), and low high-density lipoprotein (HDL) cholesterol levels. The risk of developing CVD in 
that population is approximately doubled [3].  
I n t r o d u c t i o n  
 
 
 2 
In 1988, Reaven first introduced the concept that insulin resistance clusters with glucose 
intolerance, dyslipidemia, and hypertension to increase cardiovascular risk [4].  In the 1990s, the 
so far called 'insulin resistance syndrome' changed into the clinical metabolic syndrome that has 
now taken hold in the medical literature. It has been defined and institutionalized, principally by 
the World Health Organization (WHO) [5], the Third Report of the National Cholesterol 
Education Program's Adult Treatment Panel (NCEP/ATP III) and the International Diabetes 
Federation (IDF) [3, 6-8]. As depicted in table 1, the criteria vary to some degree, but all 
definitions identify a population with increased risk for developing type 2 diabetes mellitus 
(T2DM) and CVD [5, 9, 10]. 
 
Table 1: Common definitions of the MetS 
IDF (2005) NCEP/ATP-III (2001-2005) WHO (1998) 
 Waist circumference ≥102 cm 
(men), ≥88 cm (women) 
 Plus 2 of: 
 Blood pressure ≥130/85 
mmHg or treatment  
 Triglycerides ≥150 mg/dL 
or treatment 
 HDL <40 mg/dL (men), 
<50 mg/dL (women) 
 Fasting glucose 100 
mg/dL or treatment 
At least 3 of the following: 
 Waist circumference ≥102 cm 
(men), ≥88 cm (women) 
 Blood pressure ≥130/85 
mmHg or treatment 
 Triglycerides ≥150 mg/dL  
or treatment 
 HDL <40 mg/dL (men), 
<50mg/dL (women) 
 Glucose 110 mg/dL or 
treatment  
 Insulin resistance or T2DM or 
impaired glucose tolerance 
or impaired fasting glucose  
 Plus 2 of: 
 Body mass index ≥30 
kg/m² or waist-to-hip-
ratio >0.9 (men) / >0.85 
(women) 
 Blood pressure ≥140/90 
mmHg or treatment 
 Triglycerides ≥150 mg/dL 
or treatment 
 HDL <35 mg/dL (men), 
<39 mg/dL (women) 
 Microalbuminurea 
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1.1.2 Epidemiology 
 
The prevalence of the MetS varies and is dependent on the criteria in the different definitions of 
the MetS described above, as well as the composition (sex, age, race, ethnicity) of the 
population to be examined [11]. However, independent of the criteria, the prevalence of MetS is 
high and increasing in the western world, most likely due to the obesity epidemic [12-14]. For 
example, according to the National Health and Nutrition Examination Survey (NHANES) 2003-
2006 [15], 34.0 % (age-adjusted) of the individuals having been studied met the NCEP/ATP III 
revised (2005) criteria for MetS. Males and females, 40-59 years of age, were about three times 
as likely as those 20-39 years of age to meet the criteria for MetS. Within the male and female 
groups with 60 years of age and over, the individuals were even four to six times as likely to 
meet the criteria suggesting that the prevalence of MetS increases with age.  
 
1.1.3 Pathophysiology 
 
MetS is the consequence of a complex interplay between genetic and environmental factors. 
The following paragraph exclusively focuses on the environmental determinants.  
Several lines of evidence implicate visceral adiposity as a key component of the MetS. Visceral 
fat causes a decrease in insulin-mediated glucose uptake, thus is clearly related to insulin 
resistance. The mechanisms for that probably involve adipokines being produced by adipose 
tissue, that modulate the crosstalk between metabolism and vascular function [16]. These 
include tumor necrosis factor-α (TNF-α) [17, 18], interleukin-6 (IL-6) [19-21] and eventually C-
reactive protein (CRP) [22, 23] as well as resistin [24-26] and leptin [27], which are pro-
inflammatory and contribute to insulin resistance and vascular dysfunction. The renin 
angiotensin system is also activated in adipose tissue and leads to hypertension and insulin 
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resistance [28]. In contrast, adiponectin is a protective adipokine that links insulin sensitivity 
with energy metabolism. Furthermore, adiponectin levels are decreased in obesity, T2DM and 
MetS [29] (figure 1).  
In addition to these adipokines, FFAs, which are excessively released from visceral fat due to an 
imbalance between energy uptake and expenditure as well as impaired insulin signaling, are also 
closely related to the development of insulin resistance. In the liver, FFAs serve as substrate for 
the synthesis of TG. FFAs also stabilize the production of apoB, the main lipoprotein of very-low-
density lipoprotein (VLDL) particles, resulting in more VLDL production. Moreover, the activity of 
lipoprotein lipase, the regulating factor of VLDL clearance, is decreased. Thus, 
hypertriglyceridemia in insulin resistance is the result of both an increase in VLDL production and 
a decrease in VLDL clearance. VLDL is metabolized to remnant lipoproteins and small dense LDL, 
both of which can promote atheroma formation due to a better susceptibility to be oxidized to 
oxLDL. The TGs in VLDL are transferred to HDL by the cholesterol ester transport protein in 
exchange for cholesteryl esters, resulting in TG-enriched HDL and cholesteryl ester-enriched 
VLDL particles. The TG-enriched HDL is a better substrate for hepatic lipase, so it is cleared 
rapidly from the circulation, leaving fewer HDL particles to participate in reverse cholesterol 
transport from the vasculature. All these lipid abnormalities form an atherogenic dyslipidemia 
triad of hypertriglyceridemia, low HDL levels, and small dense LDL particles [30]. 
In conclusion, visceral adipose tissue is, due to its high metabolic and inflammatory activity, the 
central player in MetS, which results in conditions such as hypertension, insulin resistance and 
finally atherogenic dyslipidemia, all leading to an increased risk to develop atherosclerosis [31, 
32] (figure 1). 
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Figure 1: Pathophysiology of the MetS (modified according to [32]). Visceral obesity is the central player in the MetS 
resulting in lipid perturbations and an altered cytokine as well as altered adipokine secretion profile. All these 
conditions finally lead to the development of atherogenic dyslipidemia and endothelial dysfunction, the major 
components in atherogenesis. Abbreviations: FFA, free fatty acids; TG, triglycerides; apoB, apolipoprotein B, LDL-c, low 
density lipoprotein cholesterol; HDL-c, high density lipoprotein cholesterol; IL-6, interleukin-6; CRP, C-reactive protein; 
TNF-α, Tumor necrosis factor-α; oxLDL, oxidized LDL.  
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1.2 Atherosclerosis 
 
Atherosclerosis is the major cause of CVD such as myocardial infarction, stroke, and ischemic 
gangrene. This group of diseases represents the main cause of death in the western world 
today. In addition, due to the increasing prevalence of CVD in developing countries and Eastern 
Europe and an accumulation of metabolic risk factors, including obesity and diabetes in the 
western world, the WHO expects CVD to become the major killer even globally. These factors 
stress the need for intensified research in combination with increased preventive approaches 
against atherosclerotic diseases.  
 
1.2.1 Initiation and early atherogenesis  
 
Hypercholesterolemia and hypertension, two major criteria of the MetS and concomitantly risk 
factors for atherosclerosis cause endothelial activation in large- and medium-sized arteries. The 
atherosclerotic process is initiated when cholesterol-rich VLDL and LDL accumulate in the intima 
[33, 34]. Afterwards bioactive phospholipids released by modified (mostly by oxidation) LDL 
particles activate the endothelial cells [35] (figure 2, left panel). In the activated state, they 
express several types of leukocyte adhesion molecules (i.e. vascular cell adhesion molecule 
(VCAM-1)), which cause blood cells such as monocytes and lymphocytes to approach the 
vascular surface in order to adhere to the site of activation [36, 37]. Once adherent to the 
endothelium, leukocytes migrate into the underlying intima in response to chemoattractant 
stimuli including chemokines, e.g. monocyte chemoattractant protein-1 (MCP-1 or also referred 
to as chemokine (C-C motif) ligand 2 (CCL2)) [38, 39] (figure 2, right panel). There is even 
evidence that gene targeting of MCP-1 can inhibit disease development [38, 39].  
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Figure 2: Initiation of atherogenesis. LDL particles penetrate the endothelium and are retained in the intima where it 
undergoes oxidative modification. Bioactive phospholipids released from LDL stimulate endothelial cells to express 
adhesion molecules such as VCAM-1 (left panel). In consequence, circulating monocytes and/ or T cells adhere to the 
vascular surface and migrate into the intima in response to chemokines (e.g. MCP-1) (right panel). Abbreviations: LDL, 
low-density lipoprotein; oxLDL, oxidized LDL; VCAM-1, vascular cell adhesion molecule-1; MCP-1, monocyte 
chemoattractant protein-1. 
 
 
1.2.2 Advanced plaque progression 
 
The macrophage-colony-stimulating factor (M-CSF) induces the entering of monocytes and their 
differentiation into macrophages. Macrophage differentiation is necessary for atherosclerosis 
[40, 41], and up-regulates pattern recognition receptors, including scavenger receptors (ScRs) 
and toll-like receptors (TLRs) [41]. ScRs amongst others mediate oxLDL internalization by 
macrophages. If cholesterol derived from uptake of oxLDL cannot be sufficiently eliminated 
from the cell, it accumulates as cytosolic droplets. This is caused by pro-inflammatory cytokines 
and endotoxins which inhibit the expression of ATP-binding cassette transporters ABCA1 and 
ABCG1 that allow the export of cholesterol from the cell [42, 43]. As a consequence, the 
macrophage forms a foam cell, the prototypic cell of atherosclerosis. Unlike to ScRs, TLRs when 
bound by ligands with pathogen-like molecular patterns (such as bacterial toxins, stress 
proteins, DNA motifs, heat shock protein 60 (HSP60), oxLDL, etc.) [44-46], initiate a signal 
I n t r o d u c t i o n  
 
 
 8 
cascade leading not only to the activation of macrophages, but also of TLR-expressing dendritic, 
mast and endothelial cells [47, 48]. Pro-inflammatory cytokines such as interleukin-1 (IL-1) and 
TNF-α can also activate macrophages. Macrophage activation leads to the release of reactive 
oxygen species, cytokines, vasoactive molecules such as nitric oxide, endothelins and 
eicosanoids [49, 50] and proteases which degrade matrix components leading to the 
destabilization of plaques and an increased risk for plaque rupture and thrombosis [51-54] 
(figure 3, upper panel).  
T cells, equally to monocytes, adhere to the vascular surface via cell adhesion molecules and 
chemokines, and then migrate into the intima. T cells in lesions recognize local peptide antigens 
such as HSP60, and microbial antigens. T cell activation can lead to several types of effector 
responses, which of them are T helper-1 (Th1), -2 and regulatory T cells. However, the Th1 
response involving the secretion of pro-inflammatory cytokines is most prevalent in atheroma. 
This finally contributes to local inflammation and growth of the plaque. Intensified inflammatory 
activation may lead to local proteolysis, plaque rupture, and thrombus formation, which cause 
ischemia and infarction [55] (figure 3, lower panel).  
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Figure 3: Macrophage activation, foam cell formation and T cell activation. Upper panel: Once the monocyte has 
migrated into the intima, the molecule M-CSF induces its differentiation into macrophages. During this process, ScRs 
and TLRs are upregulated. ScRs mediate the internalization of oxLDL by macrophages and cause the foam cell 
formation. TLRs ligated to microbial molecules, HSP60 or oxLDL as well as IL-1 and TNF-α can also activate these 
macrophages. Activated macrophages release many pro-inflammatory mediators responsible for SMC migration, 
thrombocytes aggregation and thrombus formation. Lower panel: Once the T cell has migrated into the intima, it 
searches for antigens. T cells respond to antigens such as oxLDL, HSP60 or microbial antigens. In consequence, T cells 
are activated and lead to three different effector responses, Th1, Th2 and Treg effector response. However, the Th1 
response when compared with the others is the most prevalent in atheroma due to the secretion of several pro-
inflammatory cytokines that promote lesion formation and plaque vulnerability. Abbreviations: M-CSF, macrophage-
colony-stimulating factor; ScR, Scavenger receptor; TLR, Toll-like receptor, oxLDL, oxidized LDL; IL-1, interleukin-1; TNF-α, 
tumor necrosis factor-α; SMC, smooth muscle cells; HSP60, heat shock protein 60; Th1, T helper-1; Th2, T helper-2; Treg, 
regulatory T cell. 
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1.3 Lipoprotein(a) 
 
1.3.1 Biochemistry and mechanisms of atherogenicity of lipoprotein(a) 
 
Lipoprotein(a) [Lp(a)], first discovered by Kåre Berg in 1963 [56], is a unique lipoprotein being 
formed through the extracellular association of an apoB-100-containing lipoprotein (e.g. LDL) to 
a highly glycosylated and polymorphic apolipoprotein(a) [apo(a); official gene symbol: LPA] 
secreted by hepatocytes, via a single disulfide bond [57]. The apo(a) gene further shares high 
homology with the gene of the plasminogen [58] being a protease involved in fibrinolysis. 
Due to the atherogenic and pro-thrombotic character of Lp(a), raised levels of Lp(a) are 
associated with an increased incidence of a variety of CVD, combining atherosclerosis and 
thrombosis [59].  
The mechanisms implicated in the atherogenicity of Lp(a) include self-aggregation and 
precipitation to the vascular wall, adhesion molecule production (VCAM and ICAM), avid binding 
to endothelial cells, proliferation and migration of smooth muscle cells and chemotaxis of 
monocytes [60-63]. Foam cell formation is also enhanced by Lp(a) [63]. Due to its unique 
structural homology to plasminogen, Lp(a) competes with plasminogen for binding to 
plasminogen receptors, fibrinogen and fibrin [64]. It also induces the production of plasminogen 
activator inhibitor 1 and inhibits the secretion of tissue-plasminogen activator by endothelial cells 
[65]. Lp(a) is further very susceptible to bind with oxidized phospholipids [65-68], which is then 
potentially taken up by the vessel wall and finally accelerates the development of 
atherosclerosis. 
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1.3.2 Regulation of lipoprotein(a)  
 
Lp(a) concentrations are genetically determined by apo(a) size [69], with small isoforms at 
higher concentrations and large isoforms at lower concentrations [69-75]. Thus, Lp(a) 
concentrations vary substantially between individuals. 
On the other hand, Lp(a) levels can be influenced by a limited number of physiological factors 
(such as estrogens [76], testosterone, growth or thyroid hormones), disease conditions (such as 
renal failure [77-79], or peroxisomal disorders [80]) or environmental agents (such as alcohol 
[81], HIV-1 protease inhibitors [82]). 
 
1.3.3   Treatment of elevated lipoprotein(a)  
 
Circulating levels of Lp(a) are remarkably resistant to common lipid lowering therapies [83-85]. 
One exception to effectively lower Lp(a) levels is niacin when given in high doses (2-3 g/day) [86, 
87]. These doses of niacin, however, are lowering Lp(a) only approximately by 20-30 % and can 
be associated with headaches, flushing and liver toxicity and finally non-compliance. Also, due to 
severe side effects, a slow-release formation of niacin (Tredaptive©) was recently withdrawn 
from the market in Europe (HPS2-THRIVE, EHJ Feb 2013). Aspirin at low doses was found to 
decrease Lp(a) serum levels only slightly [88] indicating rather minor importance.  
Thus, there are currently no effective treatments available for the reduction of Lp(a) apart from 
plasma aphaeresis which is costly, labor-intensive and actually intended for patients with CVD 
progression and highly elevated Lp(a) levels [89, 90]. For this reason, alternative well-tolerated 
and more convenient therapeutic approaches are required to decrease elevated Lp(a) serum 
levels. 
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1.3.4 Chronic inflammatory disease and l ipoprotein(a) 
 
Chronic inflammatory diseases (CID) are associated with an increase in CVD risk. Interestingly, in 
a recent review it has been demonstrated nicely that in humans several CIDs are associated with 
an increase in Lp(a) levels [91]. Thus, elevated Lp(a) levels in CID patients might contribute to an 
increased CVD risk in these patients. Therefore, lowering Lp(a) levels might be beneficial in 
reducing the CVD risk not only in the general population but especially in CID patients. The 
finding that Lp(a) is elevated in CID leads to the suggestion that Lp(a) is a positive acute-phase 
reactant being triggered by IL-6 as major mediator of the acute-phase response [92]. That is 
consistent with six IL-6 responsive elements (IL-6 RE) present within the human apo(a) gene 
promoter [93, 94]. In 2009, a monoclonal antibody against the IL-6 receptor, referred to as 
tocilizumab (TCZ), was approved for the treatment of rheumatoid arthritis (RA) in Europe. In a 
recent clinical study of our group it was shown that inhibition of IL-6 signaling by TCZ indeed 
lowers Lp(a) serum levels in RA patients by up to 50 % [95]. 
 
1.4 Aim of the study 
 
Due to the latter finding one may consider TCZ as a new promising approach for lowering Lp(a) 
levels in general and especially in CID patients. In order to prove for causality and to exclude 
possible confounders within the clinical study (e.g. co-medication) this thesis aims to further 
examine the ability of IL-6 to induce apo(a) expression and the ability of TCZ to inhibit apo(a) on 
a molecular level in humans in vitro and in vivo. To address this question, in the present thesis, 
molecular, cellular and physiological experiments as well as human association studies were 
combined to further analyze the relationship between IL-6, Lp(a) and TCZ in humans.  
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2. MATERIAL AND METHODS  
2.1 Material  
 
2.1.1 Chemicals 
 
Table 2: List of chemicals used in this thesis 
 Product number Manufacturer 
10x DNase buffer B0303S New England Biolabs 
2-propanol 1.09634.2500 Merck KGaA 
5x Phusion® HF Reaction Buffer F-518 Finnzymes 
Acetic acid 100 % p.a. 1.00063.2500 Merck KGaA 
Adalimumab (Humira®) (50 mg/mL)  Abbott Laboratories 
Agarose A9539 Sigma Aldrich 
Agar-Agar 5210.3 Carl Roth 
Aminocaproic acid A2504 Sigma Aldrich 
Ammoniumperoxodisulfat 9592.3 Carl Roth 
Ampicillin sodium salt A9518 Sigma Aldrich 
Biotinylated Protein Ladder 7727 New England Biolabs 
Boric acid 6943.1 Carl Roth 
Bromophenol blue sodium salt B8026 Sigma Aldrich 
Bovine serum albumin (BSA) 01400.100 biomol 
DL-Dithiothreitol (DTT) 43815 Sigma Aldrich 
Dulbecco’s Modified Eagle medium (DMEM) E15-009 PAA Laboratories 
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DNase M0303 New England Biolabs 
ethylenediaminetetraacetic acid (EDTA) 1.08417.0250 Merck KgaA 
Ethanol p.a. ≥ 99.5 % 5054.1 Carl Roth 
Fetal calf serum (FCS) SO115 Biochrom 
GelRed Nucleic Acid Stain 41003 Biotium 
GeneRuler 1 kb Ladder SM0313 Thermo Scientific 
Glycerol G5516 Sigma Aldrich 
Glycine 3908.2 Carl Roth 
4-(2-hydroxyethyl)-1 
piperazineethanesulfonic acid (HEPES) 
9105.2 Carl Roth 
HiMarkTM Pre-Stained Protein Standard  LC5699 
novex® by Life 
technologies 
Hydrochloric acid 1.00316.1000 Merck KgaA 
Interleukin-6 (IL-6) I1395 Sigma Aldrich 
Luria Bertani (LB) medium X968.2 Carl Roth 
L-glutamine M11-004 PAA Laboratories 
Methanol p.a. 4627.2 Carl Roth  
Milk powder T145.2 Carl Roth 
Nonidet P-40 Substitute (NP-40) 14060500 Roche Diagnostics 
NuPAGE 3-8 % Tris-Acetate Gel EA0378BOX InvitrogenTM 
NuPAGE Antioxidant NP0005 InvitrogenTM 
Opti-MEM® 51985-026 Gibco 
PageRuler Plus Prestained Protein Ladder #26619 Thermo Scientific 
Phosphate buffered saline (PBS) L1825 Biochrom 
Penicillin/streptomycin (P/S) P11-010 PAA Laboratories 
PhosSTOP 04906845001 Roche Diagnostics 
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Phusion® Hot Start II DNA Polymerase 
[2U/µL] 
F-549 Finnzymes 
Potassium chloride 1.04936.0500 Merck KGaA 
Protease inhibitor cocktail P8340 Sigma Aldrich 
Roti®-Fect P001.3 Carl Roth GmbH 
Rotiphorese® Gel 40 (37.5:1) T802.1 Carl Roth 
Roswell Park Memorial Institute (RPMI) 1640 F1215 Biochrom 
Sodium chloride 9265.1 Carl Roth 
Sodium deoxycholate D6750 Sigma Aldrich 
Sodium dodecyl sulphate (SDS) 04051.1 Biomol 
ß-mercaptoethanol M3148 Sigma Aldrich 
Taq DNA Polymerase [5U/µL] 18038-042 InvitrogenTM 
Tetramethylethylenediamine (TEMED) 2367.3 Carl Roth 
Tocilizumab (RoActemra®) (20 mg/mL)  Roche Group 
Tris Acetate Running Buffer LA0041 InvitrogenTM 
Tris base 4855.2 Carl Roth 
Trypsin/EDTA L11-004 PAA Laboratories 
Tumor necrosis factor alpha (TNF-α) T6674 Sigma Aldrich 
TWEEN 20® P2287 Sigma Aldrich 
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2.1.2 Machines and labware 
 
 Blotting membranes 
Roti®-PVDF 0.45 µm, T830.1, Carl Roth  
Nylon membrane Biodyne® B 0.45 µm, PALL Life Sciences 
 Filter paper 
Cat No. 1003-917, Whatman 
 Protein visualization 
Molecular Imager® ChemiDocTM XRS+ Imaging System, Bio-Rad 
 Gel electrophoresis and blotting systems 
Mini Trans-Blot® Cell, Bio-Rad 
XCell SureLockTM Mini-Cell, invitrogen 
Power Pack P25 T, Biometra 
Fastblot B34, Biometra 
Compact M, Biometra 
Safeshield Scalpel, Feather 
 Luminometer 
Mithras LB 940, Berthold 
 Spectrophotometer 
Nano drop® Spectrophotometer ND-1000, peqlab  
Mithras LB 940, Berthold 
 Incubators 
Hera Cell 150, Thermo Electron Corporation 
 Microscope 
AE 31, Motic 
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 Real-time PCR machine 
CFX Connect Real-Time PCR Dectection System, Bio-Rad 
 pH meter 
FiveEasyTM FE20, Mettler Toledo 
 Pipettes 
eppendorf research plus (2.5, 10, 20, 100, 200, 1000 µL) 
Pipetboy acu, IBS Integra Biosciences 
Pasteur pipettes, Assistent 567/2 
 Bench 
HeraSafe HS12, Thermo Electron Corporation 
 Water bath 
GFL 1003, Gesellschaft für Labortechnik mbH 
 Cell culture dishes and other plates 
24-well, 83.1836, Sarstedt 
12-well, 3513, costar 
6-well, 140675, nunc Thermo Scientific 
Ø 10 cm dishes, 83.1802, Sarstedt 
75 cm² culture flasks, 83.1813.002, Sarstedt 
Microseal ‘B’ Adhesive Seals, MSB-1001, Bio-Rad Laboratories 
Hard-Shell 96-well plates, clear well,, white shell, HSP-9601, Bio-Rad Laboratories 
Micro test protein plate, 82.1581, Sarstedt 
Cell Scraper 25cm, 83.1830, Sarstedt 
 Centrifuges 
Heraeus Multifuge 1S-R, Thermo Electron Corporation 
Micro Star 17R, VWR 
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 Analytical Machines 
COBAS INTEGRA 400, Roche Diagnostics 
 
2.1.3 Antibodies 
 
Table 3: Antibodies used for Western blot and EMSA experiments 
 Product number Manufacturer 
Primary Antibodies   
apolipoprotein(a) 5402-1 Epitomics 
HSP90α/ß sc-7947 Santa Cruz Biotechnology 
STAT3 sc-482X Santa Cruz Biotechnology 
   
Secondary Antibodies   
Anti-Rabbit IgG, HRP-linked Antibody 7074 Cell Signalling 
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2.1.4 Restriction, ligation and dephosphorylation enzymes 
 
Table 4: Restriction enzymes, ligases and dephosphorylation enzymes used for cloning and truncation of apo(a) 
promoter 
 Product number Manufacturer 
AseI R0526S New England Biolabs 
BglII R0144S New England Biolabs 
BlpI R0585S New England Biolabs 
Bsu36I R0524S New England Biolabs 
Alkaline Phosphatase, Calf Intestinal (CIP)  M0290S New England Biolabs 
EcoRV R0195S New England Biolabs 
NlaIV R0126S New England Biolabs 
SacI R0156S New England Biolabs 
T4 DNA Ligase  M0202S New England Biolabs 
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2.1.5 Commercial kits 
 
Table 5: List of commercial reaction kits 
 Product number Manufacturer 
AllPrep DNA/RNA Mini Kit  
80204 
 
Qiagen 
Bio-Rad Protein Assay Dye Reagent 
Concentrate 
#500-0006 Bio-Rad Laboratories 
Precellys® Ceramic (1.4 mm) Beads Kit 10011152 Cayman Chemical 
Clarity Western ECL Substrate #170-5060 Bio-Rad Laboratories 
Dual-Luciferase® Reporter Assay System E1960 Promega 
EndoFree® Plasmid Maxi Kit 12362 Qiagen 
HuGene 1.1 ST array 901415 affymetrix 
LightShift® Chemiluminescent EMSA Kit 89880 Thermo Scientific 
Maxima First Strand cDNA Synthesis Kit for RT-
qPCR 
K1641 Thermo Fisher Scientific 
Maxima SYBR Green/Fluorescein qPCR Master 
Mix 
K0241 Thermo Fisher Scientific 
NucleoSpin Extract II 740609.50 Macherey-Nagel 
One Shot® TOP10 Chemically Competent E.Coli C4040-03 Invitrogen 
peqGOLD Total RNA Kit 12-6834-01 PEQLAB Biotechnologie 
QIAprep® Spin Miniprep Kit 27104 Qiagen 
Quick Blunting Kit E1201S New England Biolabs 
Quick LigationTM Kit M2200 New England Biolabs 
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2.1.6 Vector constructs 
 
Table 6: Commercially purchased vector constructs used for cloning and subsequent luciferase reporter gene assays 
 Product number Manufacturer 
pGL3 basic vector E1751 Promega 
phRL-TK  Promega 
 
 
2.1.7 Buffers and solutions 
 
Table 7: Buffer compositions 
 
Buffer composition 
RIPA lysis buffer 
 
50 mM Tris-HCl 
150 mM sodium chloride 
0.5 % sodium deoxycholate 
0.1 % SDS 
1 % NP-40 
Extraction buffer A pH 7.9 
 
10 mM HEPES 
10 mM potassium chloride 
0.2 mM EDTA 
Freshly add  
1M DTT 
1:10 PhosSTOP (10x) 
1:100 protease inhibitor cocktail 
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Extraction buffer B pH 7.9 
 
20 mM HEPES 
0.4 M sodium chloride 
0.2 mM EDTA 
Freshly add  
1M DTT 
1:10 PhosSTOP (10x) 
1:100 protease inhibitor cocktail 
10x SDS running buffer 
 
60.4 g Tris base 
288 g Glycine 
20 g SDS 
H2O ad 2000 mL 
Transfer buffer 1 36.34 g Tris base 
200 mL methanol 
H2O ad 1000 mL 
Transfer buffer 2 3.03 g Tris base 
200 mL methanol 
H2O ad 1000 mL 
Transfer buffer 3 3.03 g Tris base 
200 mL methanol 
H2O ad 1000 mL 
0.5 g aminocaproic acid per 100 mL transfer buffer 3 
2x Laemmli buffer pH 7.6 128 mM Tris base 
4.6 % SDS 
10 % Glycerol  
4x SDS loading buffer  
 
0.005 % (0.01 g) bromophenol blue 
2x Laemmli buffer ad 50 mL 
before use add 1:10 β-mercaptoethanol  
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10x TBS buffer 
 
140 g sodium chloride 
4 g potassium chloride 
60 g Tris base  
pH 7.4 with hydrochloric acid 
H2O ad 2000 mL  
1x TBS/T buffer 
 
100 mL 10x TBS 
1 mL 100 % Tween® 20 
H2O ad 1000 mL 
Blocking buffer 5 % milk powder or BSA (depending on antibody 
requirements) in TBS/T 
10x TBE buffer 890 mM Tris-borate 
20 mM EDTA 
10x TAE buffer 400 mM Tris-acetate 
10 mM EDTA 
Separating gel buffer pH 8.9 1.875 M Tris base 
10 % SDS 
Stacking gel buffer pH 6.7  0.3 M Tris base 
10 % SDS 
Stacking gel (per 2) 
 
3.3 mL H2O 
6.6 mL separating gel buffer 
6.6 mL 30 % acrylamid 
150 µL 10 % APS 
15 µL TEMED 
Separating gel (per 2) 
 
4 mL H2O 
1.32 mL stacking gel buffer 
1.12 mL 30 % acrylamid 
60 µL 10 % APS 
8 µL TEMED 
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Shift gel (EMSA) (per 2) 
 
19.36 mL H2O 
1.2 mL 10x TBE 
3.2 mL 30 % acrylamid 
240 µL 10 % APS 
24 µL TEMED 
Agarose gel (1 % or 2 %, depending 
on fragment size) 
 
1 % 
1g agarose 
1x TAE buffer 
2 % 
2g agarose 
1x TBE buffer 
LB-ampicillin agar plates (per L) 25g LB-medium 
15g  agar-agar 
1 mL ampicillin [100 mg/mL] 
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2.1.8 Primers and oligonucleotides 
 
Table 8: Oligonucleotides sequences 
 
Forward 
(5’3’) 
Reverse 
(5’3’) 
Cloning 
ttgagctcTTGCGGAAAGATTGATACTATG
CT [96] 
ttagatCTTATGTTCCATTTTGGGACTGG 
[96] 
 
Promoter 
studies 
Promoter 
truncation 
 
 
 
SmaI_NlaIV_F2:  
GTGCTAGCCCGCCCACCAC 
 
SmaI_AseI_F3: 
GCGTGCTAGCCCTAATTTTATTTGG 
 
SmaI_Bsu36I_F4: 
GTGCTAGCCCTCAGGTGATCCATC 
 
SmaI_EcoRV_F5: 
CGCGTGCTAGCCCATCTTATAAC 
 
SmaI_BlpI_F6: 
GCTAGCCCTGAGCCAGTGG 
 
 
 
 
 
 
 
 
 
SmaI_BglII_F2-6: 
CAGATCTCGAGCCCGATCTTATG 
 
 
EMSAs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3’-biotin labelled 
 
IL-6 RE 1:  
CTAGTAGCTGGGATTACAGG 
 
IL-6 RE 2:  
CCAAAGTGCTGGGATTACAG 
 
IL-6 RE 3:  
TAGTAGCTGGGATGACTGGC 
 
IL-6 RE 4:  
CCCAAAATGCTGGGATTATAGGC 
 
 
3’-biotin labelled 
 
IL-6 RE 1:  
CCTGTAATCCCAGCTACTAG 
 
IL-6 RE 2:  
CTGTAATCCCAGCACTTTGG 
 
IL-6 RE 3:  
GCCAGTCATCCCAGCTACTA 
 
IL-6 RE 4:  
GCCTATAATCCCAGCATTTTGGG 
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IL-6 RE 5:  
GGTGAGGGAAGGAGTAAGGAG 
 
IL-6 RE 6:  
GTCAACAATGTCCTGGGATTGGG 
IL-6 RE 5:  
CTCCTTACTCCTTCCCTCACC 
 
IL-6 RE 6:  
CCCAATCCCAGGACATTGTTGAC 
real-time qRT-
PCR 
apo(a):   
TGCTTGAAGAAGTCCTCAAGG 
 
ß-actin:  
ACAGAGCCTCGCCTTTGC 
apo(a):  
TATCTGCTTGTGTGGGCTCC 
 
ß-actin:   
GAATCCTTCTGACCCATGCC 
 
 
2.1.9 Human cell lines and bacterial cells  
 
Human cell lines used for in vitro-experiments 
 hepatocellular carcinoma cells (HEPG2), ACC-180, Leibniz Institute DSMZ-German 
Collection of Microorganisms and Cell Cultures 
 hepatocellular carcinoma cells (HuH7), kindly provided by J. Hampe, Department of 
Internal Medicine I, University of Kiel 
 
Bacterial cells used for transformation of vector constructs 
 One Shot® TOP10 E.coli cells (similar to DH10BTM strain), Life technologies 
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2.1.10  Serum and biopsy samples of human studies 
 
All studies were approved by the local ethics committees before the commencement of the 
studies. Furthermore, all patients provided written, informed consent.  
 
TNF-α inhibition study population 
Sera of 12 rheumatoid arthritis patients were taken before and three months after anti-tumor 
necrosis factor (TNF)-α therapy in order to study the influence of this intervention on serum 
Lp(a) levels. This study design is comparable to the study published in 2010 [95]. Weight, BMI, 
age and gender distribution of the treated subjects included into the study population were 
78.3±4.7 kg, 25.1±1.3 kg/m², 52.1±4.4 years and 52.9 % male subjects, respectively.  
 
Liver biopsy study population 
Liver samples were obtained percutaneously from patients undergoing liver biopsy for 
suspected non-alcoholic fatty liver disease (NAFLD) or intraoperatively in patients in whom an 
intraoperative liver biopsy was indicated on clinical grounds such as during scheduled liver 
resection, exclusion of liver malignancy during major oncological surgery or assessment of liver 
histology during bariatric surgery. Biopsies were immediately frozen in liquid nitrogen ensuring 
an ex-vivo time of less than 40 seconds in all cases. Patients with evidence for viral hepatitis, 
hemochromatosis or alcohol consumption higher than 20 g/day for women and 30 g/day for men 
were excluded.  
 
FoCus cohort study population 
As part of the Food Chain Plus (FoCus) project [http://www.focus.uni-kiel.de], a total number of 
n=1153 human subjects were examined in order to characterize their anthropometric and 
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metabolic parameter (table 2), to perform correlation analyses between all parameters 
measured in this study and eventually to compare Lp(a) serum levels in a normal and an elevated 
homeostasis model assessment-estimated insulin resistance (HOMA-IR), CRP, IL-6, TG and BMI 
group. Within the n=1153 human subjects, 500 subjects were enrolled from the obesity 
outpatient clinic of the Department of Internal Medicine I of the University of Kiel. The other 653 
subjects were recruited from the regional registration offices as cross-sectional controls.  
HOMA-IR was calculated using the following formula: fasting glucose (mg/dL) x fasting insulin 
(µU/mL) / 405.  
 
Cut-off levels 
BMI cut-off was set according to the classification of normal-weight, overweight and obesity 
established by the WHO 2000. HOMA-IR cut-off was set at 2 knowing that the output of the 
model is calibrated to give normal β-cell function of 100% and normal IR of 1 [97]. CRP cut-off was 
set at 3.0 mg/L according to defined risk groups of CRP by the American Heart Association and 
the U.S. Centers for Disease Control and Prevention. Lp(a) cut-off was set at 300 mg/L. This is 
defined as high risk and at the same time represents a 3-fold of the value being connected to no 
or low cardiovascular risk. IL-6 cut-off (6 pg/mL) was chosen according to the reference ranges 
being established by the Institute of Clinical Chemistry of the University Medical Center in Kiel. 
Triglycerides cut-off was set at 200 mg/dL according to the guidelines of the National Cholesterol 
Education Program of the U.S. National Heart, Lung, and Blood Institute. Triglycerides serum 
levels above 200 mg/dL already represent high levels and are associated with an increased risk to 
develop CVD. 
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2.2 Methods 
 
2.2.1 Cell culture 
 
For luciferase reporter gene assays human hepato cellular carcinoma cells (HepG2) cells were 
maintained in RPMI1640 medium supplemented with 10 % fetal calf serum (FCS), 2 mM L-
glutamine, 1 % penicillin/streptomycin (P/S) at 5 % carbon dioxide (CO2) and 37°C. For quantitative 
real-time RT-PCR, EMSA as well as for western blotting experiments, human hepato cellular 
carcinoma cells (Huh7), were maintained in DMEM with high glucose (4.5 g/L), supplemented 
with 2 mM L-glutamine, 10 % FCS and 1 % P/S at 5 % CO2 and 37°C. 
For passaging, adherent cells were washed with 1x PBS in order to remove traces of FCS-
containing culture medium, afterwards detached using 1x trypsin/EDTA solution for 
approximately 5 min at 37°C and 5 % CO2. The addition of culture medium stopped trypsinization. 
Cells were then centrifuged for 5 min at 1,200 rpm at room temperature (RT). Medium was 
aspirated and the cell pellet re-suspended in fresh culture medium before being seeded into new 
plates or flasks. 
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2.2.2 Cloning and truncation of apo(a) promoter 
 
Molecular cloning is a set of experimental methods in molecular biology that are used to 
assemble recombinant DNA molecules and to direct their replication within host organisms.  
The first step is the amplification of the DNA fragment (here: apo(a) promoter) to be cloned via 
polymerase chain reaction (PCR). 
 
2.2.2.1 Amplification of apo(a) promoter by polymerase chain reaction 
The human apo(a) promoter was first amplified from human genomic DNA. Therefore, a specific 
sense primer flanking -1293 to -1270 (according to the in reference [93] published sequence, see 
2.1.8) as well as antisense primer flanking +153 to +131 of the apo(a) promoter were used to 
generate the full length promoter region. 
The following PCR reaction (table 9) and cycling conditions (table 10) were used for this 
amplification. 
Table 9: PCR reaction used for amplification of apo(a) promoter 
Components Volume 
5x Phusion® HF Reaction Buffer 6 µL 
10 mM dNTP’s 0.6 µL 
Forward Primer [100 µM] 0.15 µL 
Reverse Primer [100 µM] 0.15 µL 
Phusion Hot Start II DNA Polymerase [2 U/µL] 0.3 µL 
Human genomic DNA [50 ng/µL) 2 µL 
Nuclease-free water ad 30 µL 
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Table 10: PCR cycling conditions for amplification of apo(a) promoter 
 Temperature Time Number of Cycles 
Initial denaturation 98°C 30 s 1 
Denaturation 98°C 10 s  
Annealing 65°C 20 s 35 
Extension  72°C 45 s  
Final Extension 72°C 10 min 1 
Hold 4°C ∞  
 
2.2.2.2 Digestion with restriction enzymes 
The amplified DNA sequence afterwards needs to be ligated into a vehicle vector in order to be 
replicated by the host organism (mostly E.coli bacterium).  
Since primers were created including restriction sites for SacI and BglII, PCR products were 
directly ligated into the multiple cloning site of pGL3 basic luciferase vector once digestion of 
both vector and insert with appropriate restriction enzymes has been performed. For digestion 
reaction, 1.5 µg purified PCR product was mixed with 10x Buffer X (depending on requirements 
of restriction enzymes) and 4 µL of SacI as well as 5 µL of BglII (for Units/mL see  table 4) in a 100 
µL-reaction and incubated for 3h at 37°C. 
For truncation, the sequence of the apo(a) promoter was analyzed for their existing restriction 
sites using the ApE (A plasmid Editor) software v2.0.30. Apo(a) promoter was digested 
after/behind IL-6 responsive element 1, 2, 3, 4 and 5 resulting in five new constructs with 
different lengths. pGL3-apo(a) (1451 bp) served as construct 1 containing all IL-6 responsive 
elements. The following restriction enzymes (table 11) have been used for the new constructs: 
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Table 11: Restriction enzyme combinations used for truncation of apo(a) promoter 
 
For truncation digestion reactions, 3 µg of plasmid DNA was mixed with 10x Buffer X (depending 
on requirements of restriction enzymes) and 3 µL of each enzyme (for Units/mL see  table 4) in a 
150 µL-reaction and incubated for 3h at 37°C. 
 
2.2.2.3 Gel extraction 
Digestion reaction was run on a 2 % agarose gel in order to explicitly pick the DNA fragment 
needed for analysis. Hence, relevant bands were cut using a scalpel and again purified using the 
NucleoSpin Extract II Kit according to the manufacturer’s instructions.  
 
2.2.2.4 Blunting 
In case, in the truncation process, there was a restriction site for a restriction enzyme not being 
compatible with the Multiple Cloning Site (MCS) of the pGL3 basic luciferase vector and at the 
same time a restriction enzyme producing sticky/cohesive ends, those ends were blunted to 
allow the combination of this fragment with one of the established restriction sites (here: SmaI 
site) within the MCS of the pGL3 basic luciferase vector. For ligation of the new fragment to the 
vector, the pGL3 basic luciferase vector needed to be digested with SmaI. For blunting, the 
purified and cut DNA fragment was mixed with Blunting Enzyme Mix (according to the 
 
IL-6 responsive elements restriction enzyme size (bp) after digestion 
Fragment 2 2, 3, 4, 5, 6 NlaIV+BglII 1275 
Fragment 3 3, 4, 5, 6 AseI+BglII 1045 
Fragment 4 4, 5, 6 Bsu36I+BglII 795 
Fragment 5 5, 6 EcoRV+BglII 716 
Fragment 6 6 BlpI+BglII 152 
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manufacturer’s recommendations), 1 mM dNTP’s and 10x Buffer X in a 25 µL-reaction and 
incubated for 15 min at RT, afterwards for 10 min at 70°C to inactivate the enzyme activity.  
 
2.2.2.5 Dephosphorylation of vector DNA 
For dephosphorylation, restriction enzymes in the reaction initially needed to be heat-
inactivated for 20 min at 65°C. Afterwards, the digestion reaction including the cut and purified 
pGL3 basic luciferase vector was incubated with 5 U (sticky ends) or 15 U (blunt ends) of Alkaline 
Phosphatase (CIP) for 60 min at 37°C (sticky/cohesive) or 50°C (blunt) prior to gel extraction (see 
Gel extraction) and subsequent ligation to the insert. That was done in order to remove 
5´ phosphate groups from vector DNA. CIP-treated fragments lack the 5´ phosphoryl termini 
required by ligases, so that they cannot self-ligate. Due to problems concerning the latter, 
dephosphorylation was used to efficiently ligate vector to insert and to decrease the vector 
background on agar plates. 
 
2.2.2.6 Ligation 
For cloning of apo(a) promoter, 100 ng cut, linearized and dephosphorylated vector was 
combined with a 3-fold molar excess of cut and purified PCR product (insert), supplemented 
with 400 U T4 DNA Ligase and 10x T4 Ligase Buffer in a 15 µL-reaction and incubated overnight 
at 16°C.  
For truncation of the apo(a) promoter, 50 ng cut, linearized and dephosphorylated vector was 
combined with a 3-fold molar excess of cut, purified and blunted insert fragment,  supplemented 
with 2x Quick Ligase Buffer and 1 µL Quick T4 DNA Ligase and afterwards incubated for 5 min at 
RT in a 20 µL-reaction. Reactions were chilled on ice and subsequently used for transformation 
(see Transformation and colony PCR) or stored at -20°C. 
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2.2.2.7 Transformation and colony PCR 
The newly generated recombinant DNA molecules were now inserted into E.coli bacterial cells 
via transformation. For each transformation, one vial of One Shot® TOP10 Chemically Competent 
E.coli was thawed on ice. 2 µL of the ligation reaction was added to the cell vial and mixed gently 
and afterwards incubated on ice for 30 min. Cells were heat-shocked for 30 sec at 42°C in a water 
bath, placed on ice for 2 min. Pre-warmed S.O.C. medium was aseptically added and tightly 
closed vials were shaken horizontally for 1 h at 37°C at 225 rpm in a shaking incubator. 150 µL of 
cell suspension was then plated out on agar plates prior to incubating them overnight at 37°C. 
Colonies were picked on the next day, plated out again on a fresh agar plate and incubated 
overnight at 37°C. Colony was picked and plasmid DNA was isolated using the QIAprep® Spin 
Miniprep Kit in order to analyze for integrity of the insert via control digestion. Sequence of 
integrated insert for cloning of the apo(a) promoter was further confirmed by sequencing. 
Resulting plasmid is in the following referred to as pGL3-apo(a).  
For truncation of cloned apo(a) promoter, all picked colonies were control-digested in order to 
check the fragment sizes. In addition, due to blunt end ligation, it was necessary to screen all 
colonies for sense and antisense directed inserts as only the sense-directed constructs can be 
used for luciferase reporter gene assays. Therefore, PCR primers flanking the region of pGL3 
basic vector and promoter fragment linkage (see 2.1.8) were created and used for the 
sense/antisense-direction screening. 
The following PCR reaction and cycling conditions were used for sense/antisense direction 
colony screening: 
 
 
M a t e r i a l  a n d  m e t h o d s  
 
 
 35 
Table 12: Colony screen PCR reaction 
Components Volume 
10x PCR Buffer 3 µL 
50 mM MgCl2 0.9 µL 
10 mM dNTP’s 0.6 µL 
Forward Primer [100 µM] 0.15 µL 
Reverse Primer [100 µM] 0.15 µL 
Taq DNA Polymerase [5U/µL] 0.3 µL 
Re-suspended colony material 5 µL  
Nuclease-free water ad 30 µL 
 
Table 13: Colony screen PCR cycling conditions 
 Temperature Time Number of Cycles 
Initial denaturation 94°C 5 min 1 
Denaturation 94°C 30 s  
Annealing 57°C 30 s 35 
Extension  72°C Depending on 
fragment 
length 
 
Final Extension 72°C 10 min 1 
Hold 
4°C ∞  
 
All established promoter constructs were afterwards analyzed using luciferase reporter gene 
assays (see 2.2.3). 
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2.2.3 Luciferase reporter gene assay 
 
Luciferase Reporter Assays allow to investigate the promoter activity by measuring light output 
from luciferase enzyme that is expressed under the control of the promoter of interest. For 
transient transfection using lipofection agent Roti®-Fect, HepG2 cells were grown in 24-well 
plates to 60-70 % confluency. 0.5 µg of pGL3-apo(a) or pGL2-FAS was applied per well. To correct 
for transfection efficiency, 12.5 ng/well phRL-TK were co-transfected. Cells were subsequently 
incubated with transfection medium (Opti-MEM®, 10 % FCS, Roti®-Fect) for 24 h followed by a 
12h-incubation in serum-reduced full medium (1 % FCS). 24 h after stimulation with 10 ng/mL IL-6 
as well as 100 µg/mL tocilizumab or 100 ng/mL adalimumab (both antibodies 1h prior to IL-6 
stimulation), cells were lysed by applying Passive Lysis Buffer, and luciferase activity was 
detected in a luminometer (Berthold Mithras LB 940) using the dual luciferase reporter assay kit. 
 
2.2.4 Generation of RNA and two-step real-time RT-PCR 
 
2.2.4.1 RNA isolation 
RNA of Huh7 cells was isolated using the peqGOLD Total RNA Kit following the manufacturer’s 
instructions. RNA concentration was measured using the spectrophotometer nanodrop®. RNA 
samples were only used for further analysis if 260/280 and 260/230 ratios were below 1.8 and 2.0, 
respectively.  
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2.2.4.2 DNase digestion 
To remove residual contaminating genomic DNA from the RNA sample which was not able to be 
removed during the RNA isolation process described above, 5 µg ultrapure RNA was digested 
using DNase (2000 U/mL) supplemented with 10x DNase buffer in a 50 µL reaction for 10 min at 
37°C. To heat-inactivate the enzyme activity of DNase, a final concentration of 5 mM EDTA was 
added and incubated for 10 min at 75°C. 
 
2.2.4.3 cDNA synthesis 
DNase-digested RNA was reverse-transcribed using the Maxima First Strand cDNA Synthesis Kit 
for RT-qPCR. For this reaction 1 µg DNase-treated RNA supplemented with 5x Reaction Mix 
(containing reaction buffer, dNTP’s, oligo(dT)18 and random hexamer primers) and the Maxima 
Enzyme Mix (containing Maxima Reverse Transcriptase and RiboLock RNase Inhibitor) in a 20 µL-
reaction was initially incubated for 10 min at 25°C, afterwards for 15 min at 55°C and finally for 5 
min at 85°C. This step was performed in a thermal cycler to ensure more exact temperatures and 
to avoid excessive condensation. The 20 µL reaction was diluted 1:10 to obtain a final cDNA 
concentration of 5 ng/µL.  
 
2.2.4.4 Primer design 
Primer sequences were designed using Primer3 standard software (version 0.4.0; 
http://frodo.wi.mit.edu/primer3/), NCBI BLAST and NCBI PrimerBLAST following general 
recommendations for PCR primer design. Primer pairs were obtained from MWG Biotech AG. For 
primer sequences used in this thesis see 2.1.8. 
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2.2.4.5 Quantitative real-time PCR 
For quantitative real-time PCR, 25 ng generated cDNA was used to amplify a specific target 
sequence being determined by corresponding primers. Therefore, cDNA was mixed with the 2x 
Maxima SYBR Green/Fluorescein qPCR Master Mix as well as with forward and reverse primers 
(0.3 µM each) in a 25-µL reaction. Reaction was run in a CFX Connect Real-Time Detection System 
using the following cycling conditions: 
 
Table 14: Cycling conditions for real-time PCR  
 Temperature Time Number of Cycles 
Initial denaturation 95°C 10 min 1 
Denaturation 95°C 15 s  
Annealing depending on Tm 30 s 45 
Extension and Data collection 72°C 30 s  
Denaturation 95°C 60 s 1 
Starting temperature 55°C 60 s 1 
Melting step 55°C 10 s 80 
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2.2.5 Generation of proteins 
 
In general, all steps being involved in protein isolation were performed on ice to prevent protein 
degradation. 
 
2.2.5.1 Whole cell extracts 
To obtain whole cell extracts, cells were washed with PBS and scraped into RIPA lysis buffer (see 
2.1.7). After centrifugation at 4°C at 14,000 rpm for 30 min, supernatant was collected and frozen 
at -80°C until further analysis. 
 
2.2.5.2 Nuclear extracts 
Nuclear extracts of Huh7 cells were generated by scraping washed cells into extraction buffer A 
to separate the cytosolic fraction from the nuclear fraction and subsequently centrifuged for 1 
min at 13,000 rpm and 4°C. Remaining pellet (nuclear fraction) was re-suspended in extraction 
buffer B, vortexed for 20 min at 4°C and afterwards centrifuged for 5 min at 13,000 rpm and 4°C. 
Supernatant (nuclear extract) was collected and stored at -80°C until further analysis. 
 
2.2.5.3 Determination of protein concentration (Bradford) 
Quantification of total protein was performed using the Bio-Rad Protein Assay being a dye-
binding assay in which a differential color change of a dye occurs in response to various 
concentrations of protein.  
For determination of protein concentration of whole cell and nuclear extracts, BSA standards as 
well as samples to be analyzed were thawed slowly on ice. BSA stock of 2 mg/mL was then 
serially diluted to obtain standards from 1 mg/mL to 0.030 mg/mL (1, 0.5, 0.25, 0.125, 0.060, 0.030 
mg/mL). Samples were diluted appropriately as well, if needed. Bio-Rad Protein Assay reagent 
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(acidic dye) (diluted 1:5 with ultrapure distilled water) was mixed with diluted or undiluted 
protein solution (tested before) within the 96-well plate and measured at 620 nm in a 
spectrophotometer. Protein concentrations were calculated using the established standard 
curve and the protein’s absorbances. 
 
 
2.2.6 Western blotting 
 
Western blotting (also called protein immunoblotting) is a widely accepted analytical technique 
used to detect specific proteins in a sample of tissue homogenate or extract. 
For western blotting, 30 μg protein of whole cell extracts was added to 4x loading buffer, 
heated to 95°C for 5 min, and separated on a NuPAGE 3-8 % Tris-Acetate gel for 2 h at 150V in 1x 
Novex® Tris-Acetate SDS Running Buffer supplemented with 1:1600 NuPAGE® Antioxidant. 
HiMarkTM Pre-Stained Protein Standard served as reference marker. Proteins were transferred to 
PVDF membranes for 1.5h at 30V in 1x NuPAGE® Transfer Buffer. On the PVDF membrane 
proteins were stained with the antibodies specific to apo(a) and HSP90α/ß. Corresponding 
secondary antibodies were chosen according to the species the primary antibody was produced 
in (both anti-rabbit IgG, HRP-linked Antibody).  
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2.2.7 Electrophoretic mobility shift assay 
 
An electrophoretic mobility shift assay (EMSA) is a common affinity electrophoresis technique 
used to study protein–DNA or protein–RNA interactions. This procedure determines whether a 
protein or mixture of proteins is capable of binding to a given DNA or RNA sequence, and 
sometimes indicate whether more than one protein molecule is involved in the binding complex.  
For EMSA experiments, 5 µg of nuclear protein extract were incubated with 1 pmol 3’-end biotin 
labelled double-stranded oligonucleotides (see 2.1.8) each containing one of the six IL-6 REs 
within the apo(a) promoter [93] and 1 µg poly dI˖dC in supplied binding buffer (supplemented 
with 5 % glycerin and 1 mM EDTA) for 30 min at RT. Competitive reaction was performed under 
identical conditions adding 200fold of the amount of the respective unlabeled oligonucleotide. 
In supershift assays, 4 µg STAT-3 supershift antibody was incubated with 5 µg of nuclear extracts 
and 1 µg poly dI˖dC in binding buffer for 30 min at 15°C. Afterwards, 1 pmol 3’-end biotin labeled 
double-stranded oligonucleotide was added and again incubated for 30 min at RT. Samples were 
separated in a 4 % PAGE until approx. two third of the gel. Final analysis was performed 
according to instructions of the LightShift® Chemiluminescent EMSA Kit. 
 
 
2.2.8 Oligonucleotide liver microarray hybridization 
 
In the Department for Internal Medicine I (Prof. Hampe) of the University hospital of Kiel, for 
homogenization of five to ten milligram frozen tissue and subsequent nucleic acid isolation, 
tubes with Precellys® 1.4 mm ceramic beads and the AllPrep DNA/RNA Mini Kit were used. 
mRNA expression analysis was performed using the Affymetrix® HuGene 1.1 ST array. 
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In the scope of this thesis, further correlation analysis as to which genes are correlated with the 
LPA gene was initially performed. Next, annotating of gene symbols being positively and 
significantly (r≥0, p<0.05) correlated with the LPA gene was performed using GeneID Conversion 
Tool of the DAVID Bioinformatics Resources 6.7 software (National Institute of Allergy and 
Infectious Diseases (NIAID), NIH; http://david.abcc.ncifcrf.gov/). Converted gene list was further 
analyzed using the Functional Annotation Clustering Tool in order to select only genes being 
related to ‘acute phase response’, ‘acute inflammatory response’, ‘inflammatory response’, 
‘activation of plasma proteins involved in acute inflammatory response’, ‘regulation of 
inflammatory response’, ‘regulation of acute inflammatory response’, and ‘positive regulation of 
inflammatory response’. 
 
 
2.2.9 Statistical analysis  
 
All data are expressed as means±SEM. Statistical analysis was performed using GraphPad Prism 
Software Version 5.04. If the assumption of normal distribution of the data was not violated 
(tested using Shapiro-Wilk) Student’s t-test or ANOVA was used. In case of not normal-
distributed data the Mann-Whitney U test or Kruskal-Wallis test was applied. For correlation 
analyses, Spearman’s rank correlation coefficient was applied as all data sets to be correlated 
were non-parametric. The significance level was set at 5 % and multiple comparisons were done 
using Bonferroni or Dunn’s post test. 
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3. RESULTS  
 
3.1 Lowering of Lp(a) serum levels is specific for IL -6 inhibition 
 
Lipoprotein(a) [Lp(a)] as a highly atherogenic, pro-thrombotic lipid particle is elevated in several 
chronic inflammatory diseases. Recently, it was shown that tocilizumab (TCZ), an interleukin-6 
receptor antibody, is able to substantially (by up to 50 %) decrease elevated Lp(a) serum levels in 
rheumatoid arthritis (RA) patients [95] suggesting that there may be a direct association 
between interleukin-6 (IL-6) and Lp(a). The aim was to investigate the specificity of the ability of 
TCZ to inhibit IL-6 signaling in order to decrease elevated Lp(a) serum levels. Therefore, Lp(a) 
was measured in n=12 sera of RA patients before and after three months of anti-tumor necrosis 
factor (TNF)-α therapy with adalimumab (ADB). This experiment however showed no significant 
change of Lp(a) serum levels in response to anti-TNF-α therapy (figure 4), indicating the Lp(a) 
lowering effect of TCZ to be specific for IL-6 inhibition. 
 
Figure 4: TNF-α-antibody treatment does not decrease Lp(a) serum levels in RA patients. Data are given as 
means+SEM of n=12 patients with RA treated with TNF-α-antibody for a time period of three months. Statistical 
significance (α=0.05) was tested using Mann-Whitney U test. ns, not significant. Abbreviations: TNF-α, tumor 
necrosis factor-α; Lp(a), Lipoprotein(a); RA, rheumatoid arthritis; SEM, standard error of the mean. 
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3.2 Elevated IL-6 and IL-6-response gene CRP are strongest associated with an 
increase of Lp(a) in humans in vivo 
 
To investigate whether the direct IL-6/Lp(a) association shown in individuals receiving an anti-
TNF-α therapy, can also be confirmed in a larger study population, a human cohort (n=1153), as 
part of the FoodChainPlus (FoCus) project (see 2.1.10), was consulted. To ensure a metabolically 
‘valid’ cohort, this cohort was initially characterized regarding their metabolic and 
anthropometric parameters. Within this huge cohort, parameters such as Body Mass Index 
(BMI), blood glucose, insulin, triglycerides (TG), C-reactive protein (CRP), IL-6 as well as Lp(a) 
were measured. Homeostasis model assessment-estimated insulin resistance (HOMA-IR, 
calculation see 2.1.10) was taken to draw conclusions about grade of insulin sensitivity of the 
individuals included in the cohort.  
 
Prevalence of elevated metabolic and anthropometric parameters 
The cohort was next screened for their prevalence (table 15) of the above parameters when 
clinically evaluated as ‘elevated’ and as metabolic risk factor, respectively.  
In the FoCus cohort (n=1153), 69.30 % exhibited a BMI above 25 kg/m2, 60.97 % of the total 
number of individuals tended to be insulin resistant (set as HOMA-IR>2, see 2.1.10) rather than 
insulin sensitive (HOMA-IR<2). More than one third of the FoCus cohort study population had 
CRP serum levels above 3.1 mg/L (see 2.1.10), yet followed by 23.07 % which exhibited elevated 
Lp(a) serum levels (≥300 mg/L, see 2.1.10). 17.17 % individuals had elevated IL-6 serum levels (≥6 
pg/mL, see 2.1.10). Elevated TG serum levels (≥200 mg/dL, see 2.1.10) were present in 12.75 % of 
human subjects.  
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Table 15: Prevalence of elevated BMI, HOMA-IR, CRP, Lp(a), IL-6 and TG serum levels within the FoCus cohort. Shown is the percentage of individuals exhibiting a BMI≥25 (30) 
kg/m2, a HOMA-IR above 2, CRP serum levels above 3.1 mg/L, Lp(a) serum levels above 300 mg/L, IL-6 serum levels above 6 pg/mL and TG serum levels above 200 mg/dL of the 
FoCus cohort. In addition, mean (±SEM), minimum, 25 % percentile, median, 75 % percentile and maximum are demonstrated. Abbreviations: BMI, Body Mass Index; HOMA-IR, 
homeostasis model assessment-estimated insulin resistance; CRP, C-reactive protein, IL-6, interleukin-6; TG, triglycerides; SEM, standard error of the mean.  
 
n=1153 Prevalence Mean (±SEM) Minimum 25 % Percentile Median 75 % Percentile Maximum 
 Cut-off %       
BMI ≥ 25 (30) kg/m² 69.30 (44.93) 31.96±0.31 16.10 23.95 28.63 38.85 78.04 
HOMA-IR ≥ 2 60.97 5.28±0.31 0.04 1.50 2.484 4.83 147.60 
Fasting insulin   17.27±0.67 0.20 6.70 10.50 19.40 403.80 
Fasting glucose   103.90±1.07 49.00 88.00 95.00 105.00 448.00 
CRP ≥ 3.1 mg/L 40.16 5.02±0.25 0.90 0.90 2.10 5.70 147.80 
Lp(a) ≥ 300 mg/L 23.07 224.00±6.83 23.30 95.00 95.00 266.00 1850.00 
IL-6 ≥ 6 pg/mL 17.17 4.65±0.24 1.50 1.65 3.20 5.10 201.90 
TG ≥ 200 mg/dL 12.75 132.60±2.92 11.00 76.00 109.00 153.50 1097.00 
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Correlation analyses of metabolic and anthropometric parameters of the FoCus cohort 
To investigate the cohort for associations between the selected parameters, correlation 
analyses were performed (figure 5-7). All performed correlation analyses revealed positive, 
significant relationships and correlation strength was interpreted using the given correlation 
coefficients rs as moderate (rs=0.5-0.75), weak (rs=0.25-0.5) and negligible (rs<0.25). Correlation 
analyses of anthropometric with metabolic parameters and metabolic with metabolic 
parameters showed that HOMA-IR and BMI (rs=0.617, p<0.0000001) (figure 5A) were 
moderately correlated followed by CRP and BMI (rs=0.614, p<0.0000001) (figure 5B) and CRP 
and IL-6 (rs=0.532, p<0.0000001) (figure 5C).  
 
 
Figure 5: Moderate correlations between anthropometric and metabolic parameters of the FoCus cohort 
(n=1153). Shows scatterplots of Spearman correlation (rs, p) between (A) BMI and HOMA-IR (rs=0.617, 
p<0.0000001), (B) BMI and CRP serum levels (rs=0.614, p<0.0000001) and (C) between IL-6 and CRP serum 
levels (rs=0.532, p<0.0000001). Abbreviations: BMI, Body Mass Index; HOMA-IR, homeostasis model assessment-
estimated insulin resistance; CRP, C-reactive protein; IL-6, interleukin-6. 
 
Weak correlations were found between HOMA-IR and TG (rs=0.493, p<0.0000001) (figure 6A), 
HOMA-IR and CRP (rs=0.454, p<0.0000001) (figure 6B), BMI and IL-6 (rs=0.445, p<0.0000001) 
(figure 6C), BMI and TG (rs=0.434, p<0.0000001) (figure 6D), HOMA-IR and IL-6 (rs=0.379, 
p<0.0000001) (figure 6E) as well as between TG and CRP (rs=0.333, p<0.0000001) (figure 6F). 
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Figure 6: Weak correlations between anthropometric and metabolic parameters of the FoCus cohort 
(n=1153). Shows scatterplots of Spearman correlation (rs, p) between (A) HOMA-IR and TG serum levels 
(rs=0.493, p<0.0000001), (B) HOMA-IR and CRP serum levels (rs=0.454, p<0.0000001), (C) BMI and IL-6 
serum levels (rs=0.445, p<0.0000001), (D) BMI and TG serum levels (rs=0.434, p<0.0000001), (E) HOMA-IR 
and IL-6 serum levels (rs=0.379, p<0.0000001) and (F) between TG and CRP serum levels (rs=0.333, 
p<0.0000001). Abbreviations: HOMA-IR, homeostasis model assessment-estimated insulin resistance; TG, 
triglycerides; CRP, C-reactive protein; BMI, Body Mass Index; IL-6, interleukin-6.  
 
IL-6 was negligibly correlated with TG serum levels (rs=0.258, p<0.0000001) (figure 7A). Also, IL-
6, CRP, BMI, HOMA-IR and TG were negligibly correlated with Lp(a) (figure 7B-F). Amongst 
those, IL-6 (rs=0.102, p=0.0005) (figure 7A) and CRP (rs=0.107, p=0.0003) (figure 7B) at least 
were highest correlated to Lp(a) when compared to BMI, HOMA-IR and TG (figure 7C-E).  
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Figure 7: Negligible correlations between anthropometric and metabolic parameters of the FoCus cohort 
(n=1153). Shows scatterplots of Spearman correlations (rs, p) between (A) TG and IL-6 (rs=0.258, p<0.0000001), 
(B) Lp(a) and CRP serum levels (rs=0.107, p=0.0003), (C) Lp(a) and IL-6 serum levels (rs=0.102, p=0.0005), (D) 
BMI and Lp(a) serum levels (rs=0.093, p=0.0015), (E) Lp(a) and HOMA-IR (rs=0.073, p=0.0129) and (F) between 
Lp(a) and TG serum levels (rs=0.071, p=0.0164). Abbreviations: TG, triglycerides; IL-6, interleukin-6; Lp(a), 
Lipoprotein(a); CRP, C-reactive protein; BMI, Body Mass Index; BMI, HOMA-IR, homeostasis model assessment-
estimated insulin resistance.  
 
As this thesis aims to specifically investigate the regulation of hepatic apo(a) and eventually 
Lp(a), the following analyses will focus on Lp(a) although it is rather negligibly correlated with all 
parameters measured. However, Lp(a) serum levels have been reported to be genetically 
determined. Thus, the cohort was classified into individuals exhibiting normal and elevated 
levels of different metabolic parameters in order to exclude the genetic determinant and to 
explicitly study whether Lp(a) may be associated with one of these factors.  
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Figure 8: Elevated IL-6 and CRP serum levels and individuals exhibiting BMIs above 25 and HOMA-IR above 2 
are associated with an increase of Lp(a) in humans in vivo. This comparison analysis represents significant 
differences of Lp(a) serum levels in groups with normal (n=955) and elevated (n=198) IL-6 serum levels 
(p=0.0015) (A), in groups with normal (n=698) and elevated (n=464) CRP serum levels (p=0.0041) (B), in groups 
with BMIs below 25 kg/m2 (n=354) and above 25 kg/m2 (n=799) (p=0.0234) (C) and in groups with normal 
(n=450) and elevated (n=703) HOMA-IR (p=0.0475) (D). Lp(a) serum levels are not significantly different 
between normal and elevated TG serum levels (E). Statistical significance (α=0.05) was tested using Mann-
Whitney U test. *, p<0.05; **, p<0.01; ns, not significant. Abbreviations: IL-6, interleukin-6; CRP, C-reactive protein; 
BMI, Body Mass Index; HOMA-IR, homeostasis model assessment-estimated insulin resistance; Lp(a), lipoprotein(a); 
TG, triglycerides. 
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This analyses revealed significantly higher Lp(a) serum levels in subjects with elevated IL-6 and 
CRP compared to individuals with normal IL-6 and CRP serum levels (figure 8A+B). In addition, 
individuals with BMIs above 25 kg/m2 and with HOMA-IR above 2 also showed significantly 
higher Lp(a) serum levels when compared to their counterparts (figure 8C+D). Lp(a) serum 
levels were unchanged between TG<200 mg/dL and TG>200 mg/dL (figure 8E). 
 
3.3 Expression of typical IL-6 response genes correlates with apo(a) expression in 
human liver in vivo 
 
With the analyses of the FoCus cohort, it was found, with respect to Lp(a) pathophysiology, that 
elevated IL-6 and CRP serum levels as well as BMI above 25 kg/m2 and HOMA-IR above 2 were 
significantly associated with Lp(a) serum levels. However, IL-6 as inducer of acute phase 
response gene CRP [98] is strongest associated with Lp(a). Therefore, the following molecular 
and genetic experiments focus on IL-6 but not on CRP, BMI or HOMA-IR, as IL-6 is the initial or 
direct inducer of apolipoprotein(a) [apo(a)], the determining moiety of Lp(a) serum levels. 
The aim of the next experiment was to investigate the relationship between IL-6 and Lp(a) in the 
liver, the origin of apo(a) synthesis, instead of in serum samples. Therefore, a microarray 
experiment using liver biopsies obtained during elective surgical procedures was performed. In 
this study human subjects with BMI≥28 kg/m² were included as it is known that those individuals 
have higher hepatic IL-6 levels due to conditions such as obesity and/or non-alcoholic fatty liver 
disease (NAFLD) [99]. When correlating the hepatic apo(a) gene with inflammatory response-
associated genes, associations with several typical IL-6 acute phase response genes were found 
[100]. For example complement C9 (r=0.61677), complement C4-binding protein (r=0.60312) and 
three serpin peptidase inhibitors (table 16) were correlated with the apo(a) gene expression 
clearly indicating a relationship of the IL-6 activity and apo(a) expression in human liver in vivo.  
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Table 16: (Acute) inflammatory response-associated genes showing a significant positive correlation with the expression of the hepatic apo(a) gene. Gene symbols displayed in 
bold type are those being significantly correlated with apo(a) after adjusting the significance level α. Underlined gene symbols represent typical hepatic IL-6 acute phase response 
genes [100]. 
Gene symbol GeneID Encoded protein p-value 
Correlation  
coefficient 
r 
     
BMI < 28 kg/m² (n=13)      
αadj = 0.006     
     
CD40 958 CD40 molecule, TNF receptor superfamily member 5 0.00529 0.74176 
NUPR1 26471 nuclear protein, transcriptional regulator, 1 0.00632 0.73077 
CCL17 6361 chemokine (C-C motif) ligand 17 0.01713 0.65934 
APOA2 336 apolipoprotein A-II 0.02229 0.63736 
TIRAP 114609 toll-interleukin 1 receptor (TIR) domain containing adaptor protein 0.03029 0.60989 
IL6R 3570 interleukin 6 receptor 0.03603 0.59341 
KLKB1 3818 kallikrein B, plasma (Fletcher factor) 1 0.03603 0.59341 
CCL16 6360 chemokine (C-C motif) ligand 16 0.04254 0.57692 
TNFRSF4 7293 tumor necrosis factor receptor superfamily, member 4 0.04734 0.56593 
     
 
BMI ≥ 28 kg/m² (n=44)      
αadj = 0.0009     
     
C9 735 complement component 9 0.00001 0.61677 
C4BPA 722 complement component 4 binding protein, alpha 0.00001 0.60312 
C6 729 complement component 6 0.00009 0.56448 
ITIH4 3700 inter-alpha (globulin) inhibitor H4 (plasma Kallikrein-sensitive glycoprotein) 0.00014 0.55095 
SERPINC1 462 serpin peptidase inhibitor, clade C (antithrombin), member 1 0.00024 0.53347 
CLU 1191 clusterin 0.00036 0.52037 
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SERPINA1 5265 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 0.00038 0.51868 
SERPINA3 12 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 0.00057 0.50416 
MASP2 10747 mannan-binding lectin serine peptidase 2 0.00058 0.50388 
IGF2 3481 insulin-like growth factor 2 (somatomedin A); insulin; INS-IGF2 readthrough transcript 0.00076 0.49401 
C8A 731 complement component 8, alpha polypeptide 0.00102 0.48344 
SERPING1 710 serpin peptidase inhibitor, clade G (C1 inhibitor), member 1 0.00123 0.47611 
KLKB1 3818 kallikrein B, plasma (Fletcher factor) 1 0.00137 0.47202 
SERPINF2 5345 serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member 2 0.00187 0.45990 
CFHR5 81494 complement factor H-related 5 0.00196 0.45821 
C2 717 complement component 2 0.00294 0.44158 
C5 727 complement component 5 0.00327 0.43707 
BLNK 29760 B-cell linker 0.00395 0.42903 
IL1RAP 3556 interleukin 1 receptor accessory protein 0.00395 0.42903 
PLA2G2A 5320 phospholipase A2, group IIA (platelets, synovial fluid) 0.00479 0.42058 
IL17D 53342 interleukin 17D 0.00514 0.41748 
NFATC3 4775 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 0.00547 0.41466 
CFB 629 complement factor B 0.00561 0.41353 
PRDX2 7001 peroxiredoxin 2 0.00689 0.40409 
CDO1 1036 cysteine dioxygenase, type I 0.00732 0.40127 
C1S 716 complement component 1, s subcomponent 0.00848 0.39436 
CFI 3426 complement factor I 0.01089 0.38224 
LBP 3929 lipopolysaccharide binding protein 0.01133 0.38027 
CLU 1191 clusterin 0.01166 0.37886 
C1R 715 complement component 1, r subcomponent 0.01166 0.37886 
C1RL 51279 complement component 1, r subcomponent-like 0.01166 0.37886 
PRKCA 5578 protein kinase C, alpha 0.02150 0.34579 
CD46 4179 CD46 molecule, complement regulatory protein 0.02185 0.34616 
CYP4F11 57834 cytochrome P450, family 4, subfamily F, polypeptide 11 0.02573 0.33714 
C8B 732 complement component 8, beta polypeptide 0.02712 0.33418 
CFH 3075 complement factor H 0.02726 0.33390 
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C4BPB 725 complement component 4 binding protein, beta 0.03084 0.32685 
ORM1 5004 orosomucoid 1 0.03293 0.32304 
CXCR2 3579 interleukin 8 receptor, beta 0.03350 0.32206 
C3 718 similar to Complement C3 precursor; complement component 3; hypothetical protein LOC100133511 0.03350 0.32206 
MBL2 4153 mannose-binding lectin (protein C) 2, soluble (opsonic defect) 0.03523 0.31910 
NGF 4803 nerve growth factor (beta polypeptide) 0.03785 0.31411 
TF 7018 transferrin 0.03993 0.31163 
CX3CL1 6376 chemokine (C-X3-C motif) ligand 1 0.04003 0.31149 
IL27 246778 interleukin 27 0.04022 0.31121 
TFRC 7037 transferrin receptor (p90, CD71) 0.04145 0.30937 
IL1RN 3557 interleukin 1 receptor antagonist 0.04272 0.30754 
AOX1 316 aldehyde oxidase 1 0.04302 0.30712 
APCS 325 amyloid P component, serum 0.04302 0.30712 
NFE2L1 4779 nuclear factor (erythroid-derived 2)-like 1 0.04392 0.30585 
CCL16 6360 chemokine (C-C motif) ligand 16 0.04422 0.30543 
F2 2147 coagulation factor II (thrombin) 0.04834 0.29993 
F12 2161 coagulation factor XII (Hageman factor) 0.04834 0.29993 
KL 9365 klotho 0.04966 0.29824 
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3.4 Tocilizumab inhibits IL-6-induced expression of apo(a) in cultured human 
hepatocytes 
 
To further study the association between IL-6 and apo(a) and eventually Lp(a) mechanistically 
on different molecular levels in hepatocytes – the origin of apo(a) synthesis – cultured human 
hepatocytes were treated with IL-6 and IL-6-receptor-antibody TCZ.  
The exposure of human hepatocytes to IL-6 for 12 and 48hrs resulted in a significant 
upregulation of hepatic apo(a) at mRNA (figure 9) and protein levels (figure 10), respectively. To 
confirm that the effect of IL-6 on apo(a) is specific, the cells were co-incubated with IL-6 and IL-6 
receptor antibody TCZ. This indeed led to a significant inversion of the effect caused by IL-6 
stimulation on apo(a) mRNA (figure 9) and protein expression (figure 10) indicating the effect of 
IL-6 on apo(a) to be specific. 
 
 
Figure 9: TCZ inhibits IL-6-induced mRNA expression of apo(a) in cultured human hepatocytes. Shown are 
apo(a) mRNA expression following IL-6 and IL-6 combined with TCZ exposure for 12 hrs in whole cell extracts of 
cultured human hepatocytes, respectively. ß-actin expression served as housekeeping gene in real-time RT-PCR. 
Data are expressed in ratios of apo(a)/ß-actin and are given as means+SEM of three independent experiments, 
each performed in duplicate. Significance (α=0.05) was tested using ANOVA, *, p<0.05; **, p<0.01, ns, not 
significant. Abbreviations: TCZ, tocilizumab; IL-6, interleukin-6; mRNA, messenger RNA; apo(a), apolipoprotein(a); 
ctrl, control; hrs, hours; RT-PCR, reverse transcription polymerase chain reaction; SEM, standard error of the mean.  
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Figure 10: TCZ inhibits IL-6-induced protein expression of apo(a) in cultured human hepatocytes. Shown are 
apo(a) protein expression following IL-6 and IL-6 combined with TCZ exposure for 48 hrs in whole cell extracts of 
cultured human hepatocytes. Detection of HSP90 expression served as loading control. The shown immunoblot is 
one representative out of three independent experiments. Densitometry graphs data in this figure are shown as 
means+SEM. Abbreviations: TCZ, tocilizumab; IL-6, interleukin-6; apo(a), apolipoprotein(a); ctrl, control; hrs, hours; 
HSP90, heat shock protein 90; SEM, standard error of the mean.  
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3.5 Tocilizumab specifically inhibits apo(a) and LDLR promoter activity in cultured 
human hepatocytes 
 
In order to characterize the effects of IL-6 on apo(a) promoter activity, the full length promoter 
of apo(a) was cloned into the pGL3 basic plasmid and subsequently luciferase reporter gene 
assays in human hepatocytes were performed. In this experiment, it was found that IL-6 is able 
to activate the apo(a) promoter (figure 11A). When co-incubated with TCZ and IL-6, IL6-induced 
apo(a) promoter activity decreased down to the baseline (without stimulation) (figure 11B). 
However, having co-stimulated the cells with TNF-α inhibitor ADB, apo(a) gene promoter activity 
did not change (figure 11B) indicating the effect to be specific for IL-6. 
  
 
Figure 11: TCZ specifically inhibits apo(a) promoter activity in cultured human hepatocytes. Shown is apo(a) 
promoter activity stimulated with IL-6 (11A+11B), TCZ or ADB (11B) for 24 hrs in cultured human hepatocytes. 
Data are expressed in RLU [x-fold of ctrl] and are given as means+SEM of five independent experiments, each 
performed in duplicate. Statistical significance (α=0.05) was tested using Mann-Whitney U or Kruskal-Wallis test. 
**, p<0.01; ****, p<0.0001; ns, not significant. Abbreviations: TCZ, tocilizumab; ADB, adalimumab; IL-6, 
interleukin-6; apo(a), apolipoprotein(a); hrs, hours; RLU, relative light units; SEM, standard error of the mean. 
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In addition, it was investigated whether IL-6 only influences the determining moiety of Lp(a) – 
apo(a) – or whether also the low density lipoprotein (LDL) cholesterol metabolism which is 
being involved in Lp(a) synthesis. Therefore, the LDLR promoter cloned into a luciferase 
construct was examined as described above. In this assay, it was shown that IL-6 is able to 
induce the LDLR promoter to the same extent as the apo(a) promoter (figure 12A). When co-
incubated with TCZ and IL-6, IL6-induced LDLR promoter activity decreased down to the 
baseline (without stimulation) (figure 12B). However, having co-stimulated the cells with ADB, 
LDLR gene promoter activity did not change (figure 12B) indicating the effect to be specific for 
IL-6.  
 
 
 
Figure 12: TCZ specifically inhibits LDLR promoter activity in cultured human hepatocytes. Shown is LDLR 
promoter activity stimulated with IL-6 (12A+B), TCZ or ADB (12B) for 24 hrs in cultured human hepatocytes. Data 
are expressed in RLU [x-fold of ctrl] and are given as means+SEM of five independent experiments, each 
performed in duplicate. Statistical significance (α=0.05) was tested using student’s t-test or ANOVA. ****, 
p<0.0001; ns, not significant. Abbreviations: TCZ, tocilizumab; ADB, adalimumab; IL-6, interleukin-6; LDLR, low 
density lipoprotein receptor; hrs, hours; RLU, relative light units; SEM, standard error of the mean. 
R e s u l t s  
 
 
 58 
Next, it was examined whether the promoter of the fatty acid synthase (FAS) as an additional 
gene of lipid metabolism may also be activated by IL-6 in order to exclude unspecific metabolic 
effects. This experiment revealed that IL-6 did not activate the FAS promoter (figure 13), again 
indicating specificity of the effect of IL-6 on the apo(a) and LDLR promoter. 
 
 
Figure 13:  IL-6 does not activate FAS promoter activity in human hepatocytes. Shown is FAS promoter activity 
stimulated with IL-6 for 24 hrs in cultured human hepatocytes. Data are expressed in RLU [x-fold of ctrl] and are 
given as means+SEM of five independent experiments, each performed in duplicate. Statistical significance 
(α=0.05) was tested using student’s t-test. ns, not significant. Abbreviations: IL-6, interleukin-6; FAS, fatty acid 
synthase; hrs, hours; RLU, relative light units; SEM, standard error of the mean. 
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3.6 Tocilizumab regulates apo(a) promoter activity via a responsive element at 
position -46 to -40 
 
The apo(a) promoter contains six established IL-6 responsive elements (IL-6-RE) which is why 
the full length apo(a) promoter was truncated and six constructs generated, the first containing 
the fragment including all six IL-6-REs, the sixth only containing IL-6-RE 6 (figure 14).  
 
 
Figure 14: Schematic design of truncated apo(a) promoter constructs. Shown are all six generated constructs 
(5’-3’ direction), the first containing the fragment including all six IL-6-REs (1451 bp), the sixth only containing IL-
6-RE 6 (153 bp). Base sequences and positions of each IL-6 responsive element are displayed in each promoter 
construct pGL3-p_apo(a)_F1-F6. Start of transcription is designated as 0 (ATG start codon). Abbreviations: IL-6 
RE, interleukin-6 responsive element; bp, base pair.  
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Next, luciferase reporter gene assays were performed by incubating transfected human 
hepatocytes with IL-6 for 24 hrs in order to examine which IL6-RE/s is/are responsible for the 
transcriptional activity. The results indicated that IL6-REs 1-5 may not be important for the 
expression of the apo(a) gene whereas IL-6-RE 6 at -46 to -40 seems to be the major regulatory 
element when bound to transcription factor Signal transducer and activator of transcription 3 
(STAT3) (figure 15A). Since it was shown that only IL-6-RE 6 regulates the transcription, cells 
transfected with the promoter construct containing IL-6-RE 6 (designated as pGL3-p_apo(a)_F6 
(figure 14)) were further co-stimulated with TCZ and IL-6 showing that the effect of IL-6 is 
inhibited by TCZ (figure 15B). 
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Figure 15: IL-6 responsive element 6 of apo(a) promoter confers major transcriptional activity following IL-6-
dependent binding of transcription factor STAT3. Shown are IL-6-induced apo(a) promoter activities (in RLU [x-
fold of ctrl]) (15A) of truncated apo(a) promoter in cultured human hepatocytes (24 hrs). (15B) Shows inhibition 
of IL-6-induced promoter activity of truncated apo(a) promoter containing IL-6 responsive element 6 by TCZ. 
Data are expressed in x-fold of control and are given as means+SEM of five independent experiments, each 
performed in duplicate. Statistical significance (α=0.05) was tested using student’s t-test or ANOVA. ***, 
p<0.001; ns, not significant. Abbreviations: TCZ, tocilizumab; IL-6, interleukin-6; hrs, hours; RLU, relative light units; 
SEM, standard error of the mean.  
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To further analyze TCZ effects on apo(a), electrophoretic mobility shift assays (EMSA) were 
additionally carried out for IL-6-RE 6. This analysis showed that IL-6 specifically activated STAT3 
consequently binding to IL-6-RE 6 (figure 16). To confirm specificity of the binding of STAT3 to IL-
6-RE 6, a STAT3 antibody was used in a supershift experiment. As shown in figure 16, pre-
incubation with that antibody abolished binding of STAT3 to the IL-6-RE 6, proving specificity of 
the effect.  
 
 
Figure 16: IL-6-dependent binding of STAT3 to IL-6 responsive element 6 of apo(a) promoter for 3 hrs. Shown is 
one representative EMSA out of at least three independent experiments. STAT3 supershift antibody specifically 
blocks the DNA binding domain resulting in disappearance of the STAT3 shift (lane IL-6). Abbreviations: IL-6, 
interleukin-6; STAT3, Signal transducer and activator of transcription 3; min, minutes; 200X, 200-fold excess of non-
labelled oligonucleotide, DNA, deoxyribonucleic acid.  
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4. DISCUSSION  
 
Targeting cardiovascular risk factors is more and more considered to be important in the 
prevention of cardiovascular diseases (CVD). Modifiable cardiovascular risk factors basically 
comprise those of the metabolic syndrome such as hypertension, overweight/obesity, raised 
blood glucose and disturbances in lipid metabolism but also physical inactivity, tobacco use and 
unhealthy diet. All these factors in the long term contribute to the pathogenesis of 
atherosclerosis, the major cause of CVD. Generally lipids but specifically the LDL-cholesterol 
containing particles, amongst those lipoprotein(a) [Lp(a)], are most essential for initiating the 
atherosclerotic process (see 1.2.1).  
 
Lp(a) is a structurally and functionally unique lipoprotein consisting of the glycoprotein 
apolipoprotein(a) which is covalently bound to a LDL-like moiety [57]. The latter is composed of 
a central core of cholesteryl esters and triglycerides (TG) surrounded by phospholipids, free 
cholesterol and a single molecule of apoB [101]. The apo(a) moiety on the other hand shares a 
high degree of sequence homology (~90 %) with the corresponding sequence of plasminogen 
[58]. Both properties can potentially increase CVD risk a) via prothrombotic/anti-fibrinolytic 
effects, b) via activating monocyte adhesion via monocyte chemoattractant protein-1 [102] and 
c) via accelerated atherogenesis as a result of intimal deposition of Lp(a), cholesterol, or both 
[103] and oxidized phospholipids [104] (see 1.3). Hence, Lp(a) is thought to combine activation of 
the immune system, atherogenesis and local thrombosis; therefore being highly atherogenic. 
 
Up to date, there are no effective treatment options available except for the costly, labor-
intensive and invasive lipid aphaeresis. Niacin, when given in high doses (2-3 g/day) [86, 87], was 
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considered as approved drug to effectively lower Lp(a) levels. However, these doses of niacin 
can be associated with headaches, flushing and liver toxicity and finally non-compliance. Also, 
due to unfavorable side effects, a special slow release formation of niacin (Tredaptive©) was 
recently withdrawn from the market. Aspirin at low doses was further shown to decrease Lp(a) 
serum levels slightly [88] indicating rather minor importance. For this reason, alternative well-
tolerated and more convenient therapeutic approaches are required to decrease elevated Lp(a) 
serum levels. 
 
In a recent clinical study by our group it was shown that a single dose of intravenous (i.v.) IL-6 
receptor antibody tocilizumab (TCZ) (8 mg/kg body weight) is able to induce a profound and 
significant reduction in serum Lp(a) by up to 50 % in rheumatoid arthritis (RA) patients [95]. 
Interestingly, this effect was even more pronounced than that of niacin [105], indicating TCZ to 
be the most powerful pharmacological agent to lower Lp(a). In addition, due to the mode of 
action of TCZ to block the IL-6 receptor site, this leads to the assumption that IL-6 may be a 
major regulator of Lp(a) in vivo.  
 
To further clarify the above hypothesis, in the present thesis, Lp(a) serum levels were 
determined in RA patients (n=12) before and after receiving a tumor necrosis factor (TNF)-α-
antibody (adalimumab (ADB)) treatment for a time period of three months. This clinical trial 
served to test whether apo(a) secretion and thus Lp(a) assembly may be enhanced via any kind 
of pro-inflammatory cytokine or whether specifically IL-6 activates apo(a). Since ADB did not 
affect serum Lp(a) serum levels, this experiment clearly showed that lowering of Lp(a) due to 
TCZ is not the result of a reduction in general inflammatory activity but is a specific effect of IL-6 
on Lp(a) metabolism (figure 4).  
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To strengthen this conclusion in a larger sample size, n=1153 human subjects were enrolled in the 
scope of the FoodChainPlus (FoCus) project (see 2.1.10). This cohort was initially characterized 
regarding their metabolic and anthropometric parameters to ensure a metabolic validity of the 
study population.  
Analyzing the prevalence of overweight and obesity (BMI ≥ 25 kg/m²), insulin resistance using 
HOMA-IR, C-reactive protein (CRP), IL-6, TG and Lp(a) serum levels (table 15), it was shown that 
more than half of the study population (69.93 %) above 18 years of age exhibited a BMI above 25 
kg/m² (table 15). This nicely fits with the data from the National Health and Nutrition Examination 
Survey (NHANES), a nationally representative cross-sectional survey of the U.S. Department of 
Health and Human Diseases (Centers for Disease Control and Prevention (CDC) and National 
Center for Health Statistics), in which it was demonstrated for the time period 2009-2010 that 
69.2 % of the study sample (n=5926) above 20 years of age were overweight or obese [106]. 
44.93 % of the FoCus cohort had a BMI above 30 kg/m² (table 15). In the NHANES cohort 
however, only 35.9 % of the study sample were obese [106] suggesting in the FoCus cohort 
obesity to be basically more present than in the NHANES study. To compare the prevalence of 
obesity with NHANES in the time period the FoCus cohort was conducted, the prevalence in 
NHANES did not change between 2009-2010 and 2011-2012 [107] indicating that the increase by 
9.03 % between the FoCus cohort and NHANES is most likely not due to general changes in 
western life style but rather to the different individuals included into the cohort.  
When examining the FoCus cohort for the occurrence of impaired insulin signaling or insulin 
resistance, this analysis showed that 60.97 % of the study sample exhibited a HOMA-IR of ≥2, 
(table 15). HOMA-IR is calculated of fasting insulin and glucose serum concentrations. The 
median insulin serum concentration in the FoCus cohort was 10.50 μU/mL (table 15). Compared 
with NHANES data of 1999-2002 (n=2993 aged 20 and above) the median of fasting insulin 
concentrations was 8.95 μU/mL [108]. This fact indicates that the prevalence of disturbances in 
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insulin signaling may have increased during the last ten years. Another cause for the higher 
median in the FoCus cohort may be the higher prevalence of obesity that is associated with 
increased occurrence of insulin resistance due to low-grade inflammation. Moreover, the 
NHANES cohort was restricted to non-diabetic adults whereas in the FoCus cohort diabetics 
were not explicitly excluded. This may be an explanation for the lower insulin median in the 
NHANES study. However, since the median of fasting insulin concentrations has already risen by 
0.93 μU/mL from NHANES III 1988-1994 (n=7926) to NHANES 1999-2002 (8.02 and 8.95 μU/mL, 
respectively) [108], this change may be realistic.   
More than one third (40.16 %) of the study population of the FoCus cohort exhibited elevated 
serum levels of CRP (table 15), a marker of inflammation and identified as a risk factor for CVD 
and mortality. In the US population NHANES IV (1999-2002; n=7634) 37.2 % human subjects aged 
20 years and older had serum CRP levels above 3.1 mg/L [109] indicating a similar prevalence of 
CRP serum levels in both cohorts. Differences may be reasoned by time changes (1999-2002 vs. 
2011-now) or the higher prevalence of obesity in the FoCus cohort.  
Analyzing Lp(a) prevalence, in the FoCus cohort the mean Lp(a) serum level was 22.4 mg/dL 
being similar with data from the NHANES III study (n=2631, ≥18 years of age) of non-hispanic 
whites which reflects the ethnicity studied in the FoCus cohort. In this study mean Lp(a) serum 
levels were 20.3 mg/dL [110]. In addition, the prevalence of Lp(a) serum levels higher than 300 
mg/L representing a high risk to develop CVD (also see 2.1.10) was 23.07 % in the FoCus cohort. 
This fits nicely with the Lp(a) prevalence of a study examining n=720 healthy middle-aged 
Caucasian employers [111].   
The prevalence of elevated serum IL-6 (≥ 6 pg/mL, see 2.1.10) within the FoCus cohort was 17.17 % 
(table 15). IL-6 is just as CRP an inflammatory protein. It induces CRP through activating Janus 
kinases suggesting related roles for both proteins. Signal transducers and activators of 
transcription subsequently switch on the CRP gene expression, leading to most of the CRP 
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production [98]. This leads to the hypothesis that the IL-6 prevalence may be in a proportional 
relation to this one of CRP suggesting a similar IL-6 prevalence in the respective NHANES cohort.  
When analyzing the prevalence of elevated or high serum TG concentrations it was shown that 
12.75 % of the individuals exhibit TG serum levels above 200 mg/dL (table 15). This is considered 
as hypertriglyceridemia and connected to an increased risk for CVD. In comparison, in the 
NHANES study cohort 16.2 % of adults exhibited TG serum levels above 200 mg/dL with no 
appreciable change between NHANES 1988-1994 and 1999-2008 [112]. It is to mention at this 
point that the prevalence of high risk Lp(a) serum levels was higher than this of high risk TG 
serum levels in the FoCus cohort. Due to the higher atherogenicity of Lp(a), and also due to its 
‘double’ character of also being pro-thrombotic when compared to TG, this suggests that high 
risk Lp(a) serum levels should be paid even more attention to with respect to its 
pathophysiology and consequent treatment options alternative to lipid aphaeresis. 
 
In the FoCus cohort, moderate correlations were found for HOMA-IR and BMI (rs=0.617, 
p<0.0000001), CRP and BMI (rs=0.614, p<0.0000001) as well as CRP and IL-6 (rs=0.532, 
p<0.0000001) (figure 5).  
The correlation between HOMA-IR and BMI is in concordance with a study from Trirogoff et al. 
[113] revealing a correlation coefficient of 0.496 between HOMA-IR and BMI in n=95 non-diabetic 
chronic kidney disease patients but also in n=36 matched control subjects. These differences in 
the strength of correlation between HOMA-IR and BMI may be due to different mean BMIs 
within both cohorts (28 kg/m² vs. 31.96 kg/m³ in FoCus (table 15)) or to the lower sample size in 
this study.  
Furthermore, the significant positive association between CRP and BMI was for example verified 
in a cross-sectional European Study from Copenhagen (n=21836) [114] and in a study using 
NHANES data of n=16616 individuals [115]. Both studies showed that CRP levels were higher with 
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higher BMI providing evidence, especially due to the huge sample size, for CRP to be a marker of 
elevated adiposity. Since the cytokine IL-6 is released by human adipose tissue, and IL-6 
stimulates the production of acute phase proteins such as CRP, this might explain the observed 
associations between CRP and BMI.  
Since CRP is then released by the liver into the circulation one may assume a direct correlation 
between serum IL-6 and CRP. The association was not only confirmed in the present study 
(figure 5) but also in a British study consisting of 107 human subjects in whom a significant 
relationship between CRP and IL-6 was shown as well [116]. 
In this study, weak correlations were found between HOMA-IR and TG (rs=0.493, p<0.0000001), 
HOMA-IR and CRP (rs=0.454, p<0.0000001), BMI and IL-6 (rs=0.445, p<0.0000001), BMI and TG 
(rs=0.434, p<0.0000001), HOMA-IR and IL-6 (rs=0.379, p<0.0000001) and between CRP and TG 
(rs=0.333, p<0.0000001) (figure 6).  
An imbalance between energy expenditure and uptake results in free fatty acids (FFAs) 
excessively released from visceral fat and the up-regulation of insulin signaling-impairing 
adipocytokines. FFAs in the next step serve as substrate for the synthesis of TG and VLDL hence 
leading to hypertriglyceridemia (also see 1.1.3). According to this pathophysiology one might 
expect a direct relation between HOMA-IR and TG serum levels. That was confirmed in the 
present study (rs=0.493) (figure 6). The Korean NHANES data from 2007-2009 however showed 
that TG and HOMA-IR are significantly but rather negligibly correlated (rs=0.195 for men and 
rs=0.191 for women) in 7623 participants [117]. It is possible that the ethnicity has a substantial 
influence with respect to this correlation. That there is indeed provided evidence for ethnicity 
differences regarding this correlation was nicely confirmed by a study of Sumner et al. [118]. 
They suggested that TG serum levels are not markers of insulin resistance in African Americans. 
This was repeatedly shown in a study from the University of Yale in which an association 
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between the TG/HDL ratio and HOMA-IR in African Americans compared to white youths was 
not found [119]. Therefore, it is possible, that Korean individuals do not exert such strong 
correlations between TG and insulin resistance when compared to Caucasians, as well. However, 
clarifying studies are required with regard to this hypothesis. 
CRP has not only been reported to be positively correlated with HOMA-IR (rs=0.468) but also 
with TG (rs=0.111) in an Italian study population of n=201 [120] being in concordance with the data 
presented in this work (figure 6). However, in this study the association between CRP and TG 
was far stronger which might be due to the generally higher prevalence of obesity in the FoCus 
cohort (table 15).  
IL-6 is similarly correlated with HOMA-IR and with BMI in the FoCus study (figure 6). A very 
simple explanation might again be the release of excessive FFAs by adipose tissue and 
subsequently of many adipocytokines, e.g. IL-6, which then impair insulin signaling and induce 
the development of insulin resistance finally resulting in increased HOMA-IR. Additionally, very 
similar correlations were repeatedly shown in a study by Leinonen et al. [121] revealing a 
correlation coefficient of 0.324 (HOMA-IR) and 0.336 (BMI) in n=135 Finnish individuals.  
Inversely, as TGs were shown to be weakly correlated with HOMA-IR, BMI should also be 
correlated with TGs according to the described pathophysiology of insulin resistance. Indeed, 
this was demonstrated not only in the FoCus cohort (figure 6) but also in a study of Turcato et al. 
examining n=146 women and n=83 men [122]. 
Rather negligible but significant correlations were found between TG and IL-6 (rs=0.258, 
p<0.0001), Lp(a) and CRP (rs=0.107, p=0.0003), Lp(a) and IL-6 (rs=0.102, p=0.0005), Lp(a) and 
BMI (rs=0.093, p=0.0015), Lp(a) and HOMA-IR (rs=0.073, p=0.0129) and Lp(a) and TG (rs=0.071, 
p=0.0164) (figure 7).  
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The correlation between TG and IL-6 is in line with a study of Cardellini et al. [123] showing a 
similar correlation coefficient of 0.170 in a sample size of n=470 Italian Caucasians.  
In the FoCus cohort, a positive significant but negligible correlation was shown between IL-6 and 
Lp(a) (figure 7). As it is well-known that apo(a) is under strict genetic control [69], and as it was 
also shown that the correlation between IL-6 and Lp(a) (r=0.276, p=0.0065) alters when dividing 
into individuals having high or low apo(a) isoforms [124], the FoCus cohort was divided into a 
normal IL-6 group and an elevated IL-6 group in order to show an impact of IL-6 on Lp(a) in vivo, 
independently of the apo(a) genotype. This analysis showed, that Lp(a) is significantly different 
in both groups (figure 8) indicating a role for IL-6 in Lp(a) metabolism not only in a small study 
population (figure 4).  
IL-6 is a direct inducer of CRP. Therefore, it seems obvious, that a similar correlation and 
association between Lp(a) and CRP serum levels will be found accordingly. Indeed, in the FoCus 
cohort an almost equal correlation coefficient (rs=0.107 for CRP vs. rs=0.102 for IL-6) for the 
correlation between Lp(a) and CRP serum levels was evident. Just as for IL-6 and Lp(a), Lp(a) 
serum levels were determined in a normal and an elevated CRP group. In that analysis, 
significantly higher Lp(a) serum levels were found in the elevated CRP group (figure 8). This is in 
line with a study showing that Lp(a) serum levels are significantly increased in hemodialysis 
patients exhibiting elevated CRP levels [125]. 
BMI in the FoCus cohort was significantly associated but rather not correlated with Lp(a) serum 
levels. In contrast, for example, it was shown in a study of Lamon-Fava et al. [126] that BMI is not 
associated with Lp(a) serum levels indicating not fully elucidated data concerning that 
relationship. However, since a higher BMI is correlated with higher IL-6 (as shown in figure 6) 
and since there is now a reliable proof for the relationship between IL-6 and Lp(a), this argues 
for a positive association between BMI and Lp(a), as shown in the present thesis.
D i s c u s s i o n  
 
 
 71 
Also, the relationship of Lp(a) and insulin resistance is controversial and unproven. For example, 
decreased Lp(a) levels in response to hyperinsulinemia [127] and a negative relationship 
between Lp(a) levels and the incidence of type 2 diabetes mellitus (T2DM) have been reported 
previously [128, 129]. In contrast, some studies have shown a strong positive association 
between T2DM and elevated Lp(a) levels [130, 131]. Similar Lp(a) concentrations in subjects with 
T2DM and healthy controls have been reported in one study [132]. However, in the FoCus cohort 
a positive significant but low correlation was found (figure 7). Due to the strict genetic control 
of the apo(a) gene [69], the cohort was also classified into a group exhibiting HOMA-IR below 2 
and one group with HOMA-IR above 2 (figure 8) in order to eliminate the genetic influence. In 
this analysis though, a significant difference of Lp(a) serum levels between individuals having an 
HOMA-IR below or above 2 was found (figure 8). A cross-sectional population-based study 
(n=1030) showed that an inverse association between HOMA-IR and Lp(a) serum levels [133]. 
However, with respect to previous performed correlations in the FoCus cohort (figure 5-7), it has 
to be admitted that IL-6 was found to significantly correlate with HOMA-IR (figure 6) and Lp(a) 
serum levels to be significantly higher with higher IL-6 serum levels (figure 8A). Therefore, one 
might speculate that the positive association between HOMA-IR and Lp(a) serum levels found in 
the scope of this cohort seems realistic.  
Data on relationships between TG and Lp(a) revealed a negative significant correlation (r=−0.120, 
p<0.001) in 1200 hyperlipidemic individuals [134]. This is contradictory to the FoCus data showing 
that TG and Lp(a) are positively, even if negligibly, correlated with TG serum levels (rs=0.071, 
p=0.0164) (figure 7). However, it has to be taken into account that the FoCus cohort is not only 
composed of hyperlipidemic individuals but also of normolipidemic individuals (table 15). On the 
other hand, as this only seems to be a slight shift, the genetic variability of the apo(a) gene 
might be responsible for that, as well. 
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In conclusion, using a very representative study population including many thousands of human 
subjects (NHANES) and many other smaller human studies, the Focus cohort reflects a 
metabolically valid study population regarding the prevalence of elevated or high-risk 
parameters and also regarding the correlations between different metabolic and 
anthropometric parameters. One exception is the metabolic parameter Lp(a) which partly 
revealed contradictory data that is, as mentioned, likely due to genetic variability of the apo(a) 
gene. However, subsequent association studies between Lp(a) and the above mentioned 
parameters showed that IL-6 and IL-6 acute phase reactant CRP were strongest associated with 
Lp(a) (figure 8A+B). However, BMI and HOMA-IR were also significantly related to Lp(a) serum 
levels. Interestingly, Lp(a) serum levels rather seem to be related to inflammatory parameters 
(IL-6, CRP, BMI and HOMA-IR), as Lp(a) serum levels were not significantly different between 
the TG groups (below or above 200 mg/dL) (figure 8F). The strength of those associations is also 
reflected in the corresponding correlation coefficients of those parameters to Lp(a) (figure 7B-
F). In addition, this nicely confirms the hypothesized link between IL-6 and Lp(a) that was shown 
already in two independent experiments [95, 135] (figure 4).   
 
Therefore, in the following this thesis aimed to further examine the effect of IL-6 on hepatic 
apo(a) – the determining moiety of Lp(a) synthesis. A microarray experiment using human liver 
biopsies confirmed what was found in the aforementioned in vivo studies, since five typical IL-6 
target genes were positively and significantly correlated with the apo(a) gene expression (table 
16).  
 
The found association between IL-6 and apo(a) [69] was further investigated mechanistically on 
different molecular levels in hepatocytes – the origin of apo(a) synthesis.  
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In these experiments human hepatocytes were treated with IL-6 and IL-6 receptor antibody TCZ. 
This experiment suggested apo(a) mRNA and protein expression to be significantly induced by 
IL-6 exposure, being in agreement with the data of Kagawa et al. [136] and Ramharack et al. 
[137]. In addition to these previous reports, in the present study it was shown that IL-6-induced 
apo(a) expression is significantly inhibited by TCZ in cultured hepatocytes (figure 9, figure 10) 
supporting previous findings [95].  
To further study the apo(a) gene promoter the full length apo(a) promoter was cloned to 
investigate effects of IL-6 and TCZ as well as TNF-α and TNF-α-antibody ADB on apo(a) promoter 
activity. As shown in figure 11A+B, IL-6 did significantly induce apo(a) promoter activity and the 
IL-6 effect described in figure 11 was abolished by TCZ. The anti-TNF-α antibody ADB did not 
neutralize the IL-6-induced apo(a) promoter activity again suggesting TCZ to specifically 
decrease IL-6-triggered apo(a) expression. This is in line with the human in vivo data of figure 4 
in which Lp(a) serum levels remained unaffected following TNFα-antibody treatment. 
To show that IL-6 does not unspecifically activate other hepatic genes associated with lipid 
metabolism, cultured hepatocytes were additionally transfected with the fatty acid synthase 
(FAS) promoter and treated with IL-6. This, however, did not lead to an induction of the FAS 
promoter activity (figure 13) suggesting that the effect of IL-6 on lipid metabolism is specific for 
Lp(a) rather than an unspecific alteration of liver function. 
Promoter truncation experiments of the six established IL-6 responsive elements (RE) of the 
apo(a) promoter ranging from position -1435 to +12 (figure 14) revealed that IL-6 RE 6 confers 
major transcriptional activity (figure 15) following IL-6-dependent binding of transcription factor 
STAT3. According to Wade et al. the major transcription start site appears to occur at 141 bases 
before the translation start ATG [93]. Those 141 bases do only comprise IL-6 RE 6 (-46 to -40) but 
not 1, 2, 3, 4 or 5 and might therefore be an explanation why only IL-6 RE 6 seems to confer 
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major transcriptional activity of apo(a) (figure 15). IL-6-induced transcriptional activity mediated 
via IL-6 RE 6 was inhibited in the presence of TCZ (figure 15).  
It is known for IL-6 to induce/mediate acute phase reactions. This takes place via the JAK/STAT 
(Janus kinase (JAK)/ Signal Transducer and Activator of Transcription (STAT)) signaling. IL-6 
signals through its receptor IL-6R/IL6ST (IL-6 signal transducer or gp130), activates Janus kinases 
which in turn phosphorylate and activate STATs (signal transducer and activator of 
transcription), including STAT3. Phosphorylated Stat3 dimerize and translocate into the nucleus 
to regulate target gene transcription. For this reason, EMSAs using complementary 
oligonucleotides to each IL-6 RE and STAT3 as supershift antibody were performed in which the 
luciferase assay data were confirmed (figure 16).  
In conclusion, all these data at different levels of molecular examination suggest that IL-6 is 
indeed a major regulator of apo(a) and eventually Lp(a), and that increased apo(a) expression 
can be decreased by TCZ.  
 
However, TCZ has also been found to increase LDL-cholesterol concentrations in vivo, which is 
why some authors argued that IL-6 inhibition might negatively influence CVD risk [138]. Indeed, 
in the scope of this thesis, it was shown on a molecular level that the LDL-receptor expression in 
cultured hepatocytes is up-regulated by IL-6 and blunted by the additional exposure of TCZ 
indicating a LDL-cholesterol elevation (figure 12) [139]. However, so far all long-term studies on 
TCZ-treated patients failed to demonstrate increased CVD mortality. In this respect, it is 
important to mention that the MEASURE study [140] clearly showed that the increase of LDL-
cholesterol in TCZ-treated human subjects is mostly due to an increase in high- and normal dense 
LDL-particles whereas small-dense LDL particles being most important for atherosclerosis-
progression, are not affected by IL-6 inhibition due to TCZ [140]. In addition, paraoxonase being 
an enzyme principally responsible for protecting LDL against oxidation was significantly 
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increased in the TCZ-treated group compared to the placebo group. This might explain the 
insignificant change of oxidized LDL, well known to promote atheroma formation though (also 
see 1.2), in the TCZ-treated group compared to placebo. Therefore, from the data reported so far 
it cannot be concluded that TCZ is pro-atherogenic or is increasing CVD risk. In complete 
contrast, the data on TCZ and Lp(a) reported in two clinical trials [95, 135] and the present thesis 
suggest that TCZ indeed seems to transfer anti-atherogenicity by reducing the most pro-
atherogenic lipid particle, Lp(a). 
 
The data observed here may suggest that TCZ might be a future treatment option in patients 
with progressive CVD due to elevated Lp(a). In addition to CVD in general, these results may be 
of major importance for example in the differential therapy of RA patients for whom TCZ is 
approved. As several pharmaceutical agents are available for RA, elevated Lp(a) serum levels 
thus may be a pivotal additional indication in order to decide for the use of TCZ infusions instead 
to use e.g. TNF-α-inhibitors. In the past, the decision for the use of a biological agent was made 
mainly on disease-specific parameters. For example, in subjects with high titers of cyclic 
citrullinated peptide (CCP) antibodies rituximab is often suggested [141] and in patients who do 
not tolerate methotrexate, TCZ might be most effective [142]. The data reported here suggested 
that in the future the decision for a specific biological agent might not only be made on 
immunological disease-specific parameters but also on metabolic co-morbidities. From this point 
of view the previous two clinical trials [95, 135] and the present thesis suggest that for a patient 
suffering from both, RA and profoundly increased Lp(a) concentrations, TCZ should be the first 
choice as a first line biological agent if disease-modifying antirheumatic drug (DMARD) therapy is 
not sufficient in these subjects.  
Up to date, TCZ is only approved as a biological drug for the treatment of RA, Castleman's 
disease and systemic juvenile idiopathic arthritis. Therefore, there is need for further clinical 
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trials evaluating the efficacy and safety of TCZ in individuals not suffering from RA. Indeed, it 
was reported for Lp(a) to be elevated in many autoimmune and chronic inflammatory diseases 
(CID) such as Systemic Sclerosis, Systemic Lupus Erythematosus, Antiphospholipid Syndrome 
and RA or Crohn’s disease [91, 143]. In those, it has been shown that IL-6 production is implicated 
in the diseases’ pathogenesis [144-146] suggesting IL-6 as likely to be responsible for even higher 
Lp(a) serum levels in these patients. Thus, if TCZ in these diseases would be considered for 
treatment, this concomitantly would mean another step forward in the treatment of elevated 
Lp(a) and hence in reducing the CVD risk in even more affected patients. In addition, it would be 
interesting whether TCZ will also be able to reduce elevated Lp(a) serum levels and hence CVD 
risk, in individuals not suffering from CID.  
 
In summary, this thesis presents several lines of evidence that (1) IL-6 specifically induces apo(a) 
and eventually Lp(a) on different molecular levels in vivo and in vitro and that therefore (2) IL-6 
blockade by monoclonal antibodies might be a promising future therapy to treat elevated Lp(a) 
serum levels and to reduce CVD risk in affected patients. TCZ might therefore be a convenient 
alternative to the costly, labor-intensive and invasive lipid aphaeresis.  
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